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 12 
Summary 13 
Tumors display profound changes in cellular metabolism, yet how these changes aid the development and 14 
growth of tumors is not fully understood. Here we use a multi-omic approach to examine liver carcinogenesis 15 
and regeneration, and find that progressive loss of branched-chain amino acid (BCAA) catabolism promotes 16 
tumor development and growth. In human hepatocellular carcinomas and animal models of liver cancer, 17 
suppression of BCAA catabolic enzyme expression led to BCAA accumulation in tumors, though this was not 18 
observed in regenerating liver tissues. The degree of enzyme suppression strongly correlated with tumor 19 
aggressiveness, and was an independent predictor of clinical outcome. Moreover, modulating BCAA 20 
accumulation regulated cancer cell proliferation in vitro, and tumor burden and overall survival in vivo. 21 
Dietary BCAA intake in humans also correlated with cancer mortality risk. In summary, loss of BCAA 22 
catabolism in tumors confers functional advantages, which could be exploited for therapeutic interventions in 23 
certain cancers.  24 
 25 
Introduction 26 
 The metabolic reprogramming of cancer has been observed for decades (Pavlova and Thompson, 2016; 27 
Vander Heiden et al., 2009), yet whether this reprogramming is a general aspect of proliferation, an unintended 28 
consequence of aberrant signaling pathways, or functionally involved in the oncogenic processes remains poorly 29 
understood. Previous reports have examined numerous metabolic alterations, demonstrating that they support tumor 30 
growth by meeting the energetic, biosynthetic, and redox needs of rapidly dividing cancer cells (Pavlova and 31 
Thompson, 2016). However, further examination has frequently shown that many of the same pathways are also 32 
used by normal proliferating cells (Pearce and Pearce, 2013), and therefore targeting these may not provide 33 
therapeutic effects without unintended consequences. The liver is one of the few organs that have the capacity to 34 
completely regenerate after partial resection. Thus, analysis of liver regeneration and oncogenesis provides a unique 35 
opportunity to understand both benign and malignant proliferative processes, respectively.  36 
 Liver cancer itself is a major health burden as the second leading cause of cancer-related death (Kladney et 37 
al., 2010). Predominantly of the hepatocellular carcinoma (HCC) subtype, tumors can develop due to a range of 38 
etiological factors, including Hepatitis B (HBV) or Hepatitis C (HCV) infection, alcohol consumption, as well as 39 
metabolic perturbations leading to non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis 40 
(NASH). HCC is typically diagnosed late in the disease progression where treatment options are limited, causing 41 
disease-free survival rates to remain dismal (Yang and Roberts, 2010). Recent genetic profiling has shown that 42 
HCCs display a preponderance of mutations affecting p53, the Wnt-β-catenin pathway, and the PI3K-AKT-mTOR 43 
pathway (Ally et al., 2017; Schulze et al., 2015). However, targeting these for effective preventive or therapeutic 44 
interventions has remained difficult and largely unsuccessful. Thus, identification of additional factors or alternative 45 
methods for intervention remains a high priority. In an attempt to identify targetable tumor-specific pathways, we 46 
used unbiased comprehensive transcriptomic and metabolomic analyses to characterize human tumors, cancer cell 47 
lines, and animal models of liver cancer and regeneration. 48 
 49 
Results 50 
Progressive Loss of BCAA Catabolism in Hepatocellular Carcinoma Development and Progression 51 
First, we analyzed a cohort of 48 HCC patients seen at Singapore General Hospital (Figure S1A). Transcriptomic 52 
profiling and differential expression analysis of matching tumor and adjacent nontumor liver tissue samples returned 53 
3624 significant genes (Figure S1B). To help focus the large gene set, as well as validate the findings and ensure 54 
robustness, we compared expression changes to an independent, well-characterized HCC cohort from The Cancer 55 
Genome Atlas (TCGA-LIHC) (Ally et al., 2017). As expected, there was an overall direct correlation between the 56 
two datasets, and use of a stringent significance threshold (p<1x10-8) returned 1405 genes that were potently altered 57 
in both cohorts (Figures 1A and 1B). KEGG pathway analysis of this gene set identified branched-chain amino acid 58 
(BCAA) degradation as the most significant pathway (Figure 1C). Approximately 40 enzymes are involved in 59 
BCAA catabolism, and with exception of the reversible transamination step performed by BCAT1 and BCAT2 60 
(Figures S1C-S1E), we found that the transcripts were broadly suppressed in tumors (Figure 1D). The first two 61 
critical irreversible steps of BCAA catabolism involve the branched-chain ketoacid dehydrogenase (BCKDH) 62 
complex and acyl-CoA dehydrogenase (ACAD) enzymes (Shin et al., 2014). Western blot and 63 
immunohistochemistry analysis demonstrated that tumors had a potent and robust downregulation of proteins 64 
involved in these catalytic steps, namely BCKDHA, ACADS, and ACADSB (Figure 1E). Biopsies from an 65 
additional independent cohort immunostained by The Human Protein Atlas (Uhlen et al., 2015) confirmed that the 66 
BCAA catabolic enzymes are broadly downregulated at the protein level (Figures 1F and S1F). Accordingly, tumors 67 
displayed a sharp reduction of BCKDH complex activity in an ex vivo enzymatic assay (Figure 1G). 68 
 Next, we performed targeted metabolomic analyses for amino acids, organic acids, and acylcarnitines on the 69 
paired tumor and adjacent nontumor liver tissues (Figures 1H and S1G). Among the noteworthy changes in tumors, 70 
we observed a significant increase in lactate, acetyl-carnitine, and numerous long chain acylcarnitines, as well as a 71 
significant decrease in multiple medium chain acylcarnitines (Figure 1H). Importantly, there was also a significant 72 
increase of all three BCAAs, and a significant decrease of downstream BCAA-derived metabolites in tumors (e.g. 73 
C3 acylcarnitine), which is consistent with a decreased BCAA catabolic flux. 74 
 Notably, the transcript levels of BCAA catabolic enzymes were not only suppressed in tumors when 75 
compared to adjacent normal tissue, but the degree of suppression correlated with multiple indicators of disease 76 
progression and tumor aggressiveness, including stage, grade, vascular invasion, lymph node invasion, and distant 77 
metastasis (Figure 1I). We also examined whether tumor etiology (e.g. Hepatitis B-, Hepatitis C-, alcohol-, and 78 
NAFLD-associated), liver inflammation, and patient race/ethnicity had any influence on BCAA catabolic enzyme 79 
expression. However, after factoring in differences in tumor grade, stage, and invasion, all groups had comparable 80 
changes (Figure S1H).  81 
 Expression levels of the catabolic enzymes were also strongly associated with clinical outcome, even when 82 
adjusting for patient and tumor characteristics (Figure S1I). Maintaining high expression of these enzymes, therefore 83 
allowing efficient catabolism of BCAAs, was associated with significantly better patient outcome. Surveying the 84 
prognostic utility of aggregating multiple (up to 5) genes identified the combined expression index of BCKDHA, 85 
ACADS, and ACADSB as the most robust predictor of patient survival in both cohorts (Figure 1J). The bifurcation in 86 
patient survival was most dramatic among high-grade tumors, with a 54-point difference in survival at 5 years (88% 87 
versus 34%; Figure 1J). Thus, the transcriptomic, enzymatic, and metabolomic analyses suggest that suppression of 88 
catabolic enzymes in HCC spare the BCAAs from degradation, leading to their accumulation in tumors. The data 89 
also suggest that the loss of BCAA catabolic enzyme expression in tumors is positively selected for during disease 90 
progression, and that it has a significant impact on patient outcome. 91 
 92 
BCAA Catabolism is Suppressed in Tumors, but Not Regenerating Liver Tissues 93 
Given that the metabolic needs of proliferating cancer cells are potentially similar to normal proliferating 94 
hepatocytes, we questioned whether the suppression of BCAA catabolism was unique to tumors, or also observed in 95 
liver regeneration. Thus, we examined multiple in vivo animal models and performed similar comprehensive 96 
transcriptomic and metabolomic analyses. Tumor and nontumor tissues were harvested from animals administered 97 
diethylnitrosamine (DEN), as this compound generates endogenous tumors resembling poor-prognosis HCC by 98 
causing multiple stochastic DNA mutations in the liver (Heindryckx et al., 2009). We also used the syngeneic 99 
orthotopic Morris Hepatoma 3924a model to represent aggressive, fast-growing tumors. KEGG analysis of all 100 
significant, differentially expressed genes shared among the tumor models confirmed that BCAA catabolism ranked 101 
as the top pathway (Figure S2A). Importantly, BCAA catabolism remained the most significant pathway even after 102 
omitting genes differentially expressed in proliferating hepatocytes after partial hepatectomy (Figures 2A, 2B and 103 
S2B-F). Indeed, while tumors had reduced expression, regenerating tissues actually enhanced the expression of 104 
BCAA catabolic enzymes modestly (Figure 2C). An initial non-targeted screen of over 200 metabolites identified 105 
five that had accumulated in liver tumors with high significance, but not regenerating tissues, and among these were 106 
all three BCAAs (Figure S2G). Subsequent targeted analyses confirmed that the BCAAs and only three other amino 107 
acids (phenylalanine, methionine, and asparagine) had accumulated in both tumor models but not regenerating 108 
tissues (Figure 2D). Accordingly, there was a significant decrease of downstream BCAA-derived metabolites (e.g. 109 
C5:1 acylcarnitine) in tumors but not regenerating tissues (Figure 2E). 110 
 We next examined the protein levels and enzymatic activity of normal, tumor and regenerating liver tissues. 111 
Of note, in addition to suppression of total protein levels, inhibition of BCKDH complex’s activity can also be 112 
achieved by phosphorylation of the BCKDHA subunit by the kinase BCKDK (Lynch and Adams, 2014; Shin et al., 113 
2014). We observed that while Morris Hepatoma tumors had sharp reductions in total protein levels of the BCAA 114 
catabolic enzymes, DEN-induced tumors displayed more overt changes in BCKDHA phosphorylation (Figure 2F). 115 
Relative to normal (DEN-free) liver tissues, the phospho/total BCKDHA ratios were elevated in DEN-exposed pre-116 
tumor tissues, and even further increased in tumors (Figures 2G and S2H). Correspondingly, BCKDK was 117 
overexpressed in pre-tumor and tumor tissues of the animal tumor models, as well as human HCC (Figures 2H and 118 
S2I). BCKDH enzyme activity assays confirmed that regardless of the primary method of suppression, all animal 119 
tumor tissues tested had significantly reduced catabolic capacity (Figures 2G and S2J). Importantly, phospho/total 120 
BCKDHA ratios, BCKDH activity, and BCKDK expression remained unchanged in regenerating tissues (Figures 121 
2G and 2H). Based on the concept of the ex vivo BCKDH assay, we also developed a hyperpolarized 13C magnetic 122 
resonance spectroscopy method (Lee et al., 2013) to quantify enzyme activity in vivo (Figure 2I). Using this 123 
platform, we detected significantly reduced BCKDH activity in the livers of rats bearing DEN-induced tumors 124 
(Figures 2J and S2K), indicating that this method can be used to noninvasively monitor enzyme activity in live 125 
subjects. Overall, these data demonstrate that in contrast to liver tumorigenesis, proliferating hepatocytes of the 126 
regenerating liver do not display decreased BCAA catabolism or an increase in BCAA content.  127 
 128 
BCAA Catabolic Enzyme Expression in Tumors is Associated with Copy Number and Transcription Factor 129 
Changes 130 
To understand what may govern the broad and robust change in BCAA catabolic enzymes, we next examined 131 
potential factors regulating their expression. No significant difference in promoter methylation of the BCAA 132 
catabolic enzymes or associations with changes in microRNA expression was observed (data not shown). In contrast, 133 
we noted that the most potent decrease in BCAA catabolic enzyme mRNA expression was from tumors with 134 
somatic copy number variation (CNV) loss (Figures 3A and 3B).  The frequency of CNV loss varied by gene, but on 135 
average affected approximately 20% of HCCs (Figure 3B). However, tumors with normal CNVs still displayed 136 
reduced gene expression relative to normal tissues, suggesting that additional regulatory mechanisms are possibly 137 
involved (Figure 3A). Thus, to identify potential regulating transcription factors, we performed upstream analysis 138 
using all significant, differentially expressed genes in human liver cancers and animal tumor models, as well as 139 
specifically the BCAA catabolic enzymes. Ingenuity Pathway Analysis (IPA) predicted significant changes in the 140 
activity of multiple metabolic transcription factors, most notably PPARα (Figure S3A). PPARα was also among a 141 
subset of transcription factors whose expression correlated with tumor aggressiveness and patient survival (Figures 142 
S3B and S3C). TRANSFAC analysis demonstrated that PPARα binding motifs were enriched in the promoters of 143 
genes differentially expressed in liver cancers, in particular the BCAA catabolic enzymes (Figure S3D). ENCODE 144 
ChIP-seq data also confirmed that PPARα bound to these promoters in the basal state (Figure S3E).  145 
 To further investigate expression changes, we examined a panel of human liver-derived cell lines. Of note, 146 
expression patterns of the BCAA catabolic enzymes in the cell lines were consistent with human and animal liver 147 
cancers. Specifically, relative to the well-differentiated, nontumorigenic cell line HepG2, the tumorigenic HCC cell 148 
lines had reduced expression of the BCAA catabolic enzymes at both the mRNA and the protein level (Figures 3C 149 
and 3D). Consistent with the upstream analyses, knocking down PPARα, or repressing its transactivation with the 150 
antagonist GW6471 significantly suppressed BCAA catabolic enzyme expression in HepG2 cells (Figures 3E and 151 
S3F). Collectively, these data suggest that changes in somatic copy number and transcription factor function likely 152 
account for the observed downregulation of BCAA catabolic enzyme expression in liver tumors. 153 
 154 
BCAA Catabolism Regulates mTOR Activity and In Vitro Cell Proliferation 155 
Like numerous other cancers, HCCs frequently harbor mutations in proteins that mimic chronic growth factor 156 
stimulation to the mammalian target of rapamycin complex 1 (mTORC1) (Ally et al., 2017; Sanchez-Vega et al., 157 
2018; Schulze et al., 2015). Previous reports have shown that activation of mTORC1 potently enhances cell growth 158 
and tumorigenesis in numerous human cancers and animal tumors models, including liver cancer (Kenerson et al., 159 
2013; Menon et al., 2012; Villanueva et al., 2008). Consistent with this, we observed that the human HCCs and 160 
animal tumor models we analyzed overexpressed and/or displayed hyperactivation (i.e. hyperphosphorylation) of the 161 
downstream mTORC1 effectors S6K and S6 (Figures 4A and S4A). Moreover, gene set enrichment analysis 162 
(GSEA) demonstrated that active mTORC1-related signatures were enriched in tumors of both human HCCs and the 163 
animal tumors models (Figure S4B).  164 
 mTORC1 integrates signals from both growth factors and nutrient abundance, and removal of either input is 165 
sufficient to block its activity (Sancak et al., 2008). Significant progress has been made recently in identifying the 166 
protein complexes and signaling cascades involved in mTORC1-related nutrient sensing (Shimobayashi and Hall, 167 
2016). Specifically, key metabolites lead to the activation of the Rag proteins, which recruit mTORC1 to the 168 
lysosome so that Rheb can activate mTOR (Sancak et al., 2008). Leucine in particular has a unique role in regulating 169 
this process in that its removal, even in the presence of other amino acids, inactivates the Rag proteins (Sancak et al., 170 
2008). While mutations activating the growth factor arm of mTORC1 are relatively common, whether the nutrient 171 
sensing arm of mTORC1 is altered in tumors has not been thoroughly explored previously. Examining the TCGA 172 
datasets, we observed that mutations impacting the currently identified proteins of mTORC1’s nutrient sensing arm 173 
are extremely rare in HCC and other cancers (Figure S3G). Thus, we hypothesized that reduced BCAA catabolism 174 
and enhanced tissue BCAA accumulation may be a primary mechanism utilized by tumors to facilitate the chronic 175 
activation of mTORC1. To examine this possibility, we undertook a series of in vitro experiments manipulating the 176 
BCAA catabolic and mTORC1 pathways. First, to recapitulate the loss of BCAA catabolic enzyme activity in 177 
tumors, we targeted a key subunit of the BCKDH complex in the immortalized hepatocyte cell line AML12. 178 
Consistent with our hypothesis, knocking down BCKDHA with inducible shRNAs raised intracellular BCAA 179 
content, enhanced mTORC1 activity, and increased cellular proliferation rates (Figures 4B and S4C). Moreover, 180 
normalizing mTORC1 activity with the inhibitors Rapamycin or Torin 1 returned proliferation rates to baseline 181 
levels (Figures 4B and S4C).  182 
 BCAAs are essential amino acids and therefore not produced endogenously. Thus, we examined whether 183 
restricting the supply or restoring the catabolism of BCAAs influenced liver cancer cell proliferation in vitro. 184 
Typical cell culture media preparations have BCAAs in far excess of physiological levels, and reducing or removing 185 
BCAAs significantly suppressed mTORC1 activity and proliferation rates of the HCC cell line Hep3B (Figure 4C). 186 
In contrast to Kras-driven pancreatic cancer cells (Palm et al., 2015), supplementing Leucine- or BCAA-starved 187 
liver cancer cells with albumin or other protein sources (either alone or in combination with the mTOR inhibitors 188 
Rapamycin or Torin 1) failed to rescue proliferation rates (Figure S4D). Similar to restricting the supply of BCAAs, 189 
restoring expression of the BCAA catabolic enzymes BCKDHA, ACADS, or ACADSB also caused mTORC1 190 
activity and cell proliferation to significantly decrease (Figure 4D).  191 
 Given the enhanced expression of BCKDK in animal tumor models and human HCC, and the attractiveness 192 
of kinases as drug targets, we also examined whether inhibiting the activity of this kinase could restore BCAA 193 
catabolism and suppress cancer cell proliferation. Indeed, CRISPR-Cas9-mediated knockout of BCKDK in Hep3B 194 
cells reduced proliferation rates and mTORC1 activity (Figures 4E and S4E). As a complementary approach, we 195 
utilized BT2, an established compound that specifically inhibits BCKDK (Tso et al., 2014). As expected, treating 196 
Hep3B cells with BT2 also caused a dose-dependent decrease in cell proliferation and mTORC1 activity (Figure 4F). 197 
The suppression of mTORC1 activity and cell proliferation was also consistent across the panel of HCC cell lines, 198 
and cell line sensitivity to BT2-mediated growth inhibition was analogous to Rapamycin and Torin 1 sensitivity 199 
(Figures 4G and S4F-I).  200 
 Removal of the nutrient sufficiency signal, such as after total amino acid withdrawal, causes mTOR to move 201 
from an active, lysosomal localization to an inactive, diffuse cytosolic localization (Sancak et al., 2010) (Figure 4H). 202 
We observed that BT2 treatment induced a similar dispersion of mTOR, suggesting it suppressed mTORC1 by 203 
modulating the nutrient sensing arm (Figure 4H). Accordingly, expressing constitutively active mutant Rag proteins 204 
(RagBS75L/RagCQ99L) (Sancak et al., 2008), or a key component of the mTORC1 complex constitutively targeted to 205 
the lysosome (Raptor-Rheb15) (Sancak et al., 2010), rendered cells resistant to BT2-mediated mTORC1 inhibition 206 
(Figure 4I). Sestrin 2 is believed to be a primary leucine sensor that regulates the Rag proteins through the GATOR1 207 
and GATOR2 complexes (Chantranupong et al., 2014). Consistent with this role, a similar resistance to BT2-208 
mediated mTORC1 inhibition was also observed in Sestrin 1/2/3 knockdown cells (Figure 4J). Collectively, these 209 
data demonstrate that BCAA supply and catabolism regulate cancer cell proliferation and mTORC1 activity, and 210 
suggest that loss of BCAA catabolism in tumors can help sustain chronic mTORC1 activation. 211 
 212 
High Dietary BCAA Intake Enhances Tumor Development and Growth In Vivo 213 
We next explored how manipulating BCAA levels may influence the development of tumors in vivo. Because 214 
essential amino acids are derived from dietary sources in vivo, we fed DEN-injected mice purified diets with 215 
standard or high levels of BCAAs (Table S1). Given the influence of fatty acids on BCAA accumulation (Newgard 216 
et al., 2009), we examined the effects in diets with either standard low (LFD) or high (HFD) fat content. Five 217 
months after DEN injection, at a time when no tumors developed in mice fed the control LFD, mice fed diets with 218 
high fat and/or BCAAs had a tumor incidence of 20-40% (Figure 5A). Moreover, of the tumors that did develop, the 219 
largest were from mice fed high BCAA diets (Figure 5B). By 8 months post-injection, mice fed high BCAA diets 220 
had a potent increase in both tumor number and size (Figures 5D-F). Notably, at both time points, the liver masses 221 
of DEN-injected mice fed high BCAA diets were elevated, while this was not observed in uninjected mice (Figures 222 
5C and 5G). This suggests that the dietary BCAAs may influence liver tissues predisposed to tumorigenesis, but 223 
have minimal impact on healthy liver tissues. Accordingly, normal liver tissues of uninjected mice responded to 224 
diets high in BCAAs or fat by enhancing the expression of BCAA catabolic enzymes (Figure 5H). In contrast, 225 
BCAA catabolic enzymes were significantly suppressed in nontumor tissues of DEN-injected mice, even further 226 
suppressed in tumors, and largely failed to increase in response to high BCAAs or fat (Figures 5H, and S5A).  227 
 Metabolomic analyses of liver tissues revealed that significant BCAA accumulation had occurred in 228 
nontumor liver tissues of mice fed high BCAA diets at both time points, while this was not consistently observed for 229 
other amino acids or metabolites (Figures 5I and S5B-D). Interestingly, the BCAA content of nontumor liver tissues 230 
directly correlated with tumor multiplicity (Figure 5I). High dietary BCAAs also enhanced the accumulation of 231 
BCAAs in tumors, which was associated with tumor sizes of the experimental groups (Figures 5F and 5J). As 232 
expected, inflammation was enhanced in livers developing tumors and/or exposed to a HFD, although dietary 233 
BCAA content appeared to have minimal impact on overall immune responses (Figure S5E). Moreover, high dietary 234 
BCAAs did not enhance DNA damage, fibrosis, or cell death leading to compensatory proliferation (Figures 5K and 235 
S5F,G), additional factors that influence liver tumorigenesis . Rather, in agreement with in vitro data, the mTORC1 236 
pathway was hyperactivated in liver tissues of mice fed high BCAA diets (Figures 5L). Thus, tissue BCAA content 237 
is directly related to liver tumor development and size, which is dependent on dietary intake of the BCAAs. 238 
 239 
Enhancing BCAA Catabolism or Restricting Dietary BCAAs Limits Tumor Burden 240 
We then investigated whether limiting BCAA accumulation through enhanced catabolism or dietary restriction 241 
could limit tumor burden. Administration of the BCKDK inhibitor BT2 at low doses through the diet (200mg per kg 242 
of diet) was able to significantly reduce the tumor burden of DEN-injected mice fed high BCAA diets (Figures 6A 243 
and 6B). Similar trends were also observed in DEN-injected mice fed chow diets with BT2 (Figure S5H). Notably, 244 
this compound was well tolerated for the duration of the study and did not lead to any observable adverse side 245 
effects. Next, to restrict the supply of BCAAs in vivo, we fed mice diets with a 50% reduction in BCAA content (as 246 
essential amino acids they cannot be completely removed long term; Table S1). All DEN-injected mice fed a low 247 
BCAA diet survived the study duration, while this was true for only 70% of mice fed normal or high levels of 248 
BCAAs (Figure 6C). Upon sacrifice, mice fed low BCAA diets also had significantly smaller tumors and reduced 249 
liver BCAA content (Figures 6D-6F). Importantly, normal lean body mass and liver function was maintained in both 250 
DEN-injected and control mice fed low BCAA diets (Figures 6G-I and S5I,J). The effects of the high and low 251 
BCAA diets were not due to differences in protein intake, as the tumor burden of mice fed diets adjusted for total 252 
protein content were similar (Figure 6J). Overall, these data show that BCAA accumulation is critical for the 253 
development and growth of liver tumors in vivo, and that dietary interventions influence tumor progression and 254 
overall survival. 255 
 256 
Comparison of BCAA Catabolism Across Cancers 257 
Given the robust changes of the BCAA catabolic enzymes in HCCs, we examined how they may be similar to, or 258 
distinct from, expression changes in other cancers. To characterize expression patterns in the development of various 259 
cancers, we performed differential expression analysis on all individual cancer subtypes profiled by TCGA with at 260 
least five adjacent normal samples for appropriate comparison (16 cancers in total). Overall, approximately 70% of 261 
cancers displayed significant suppression of at least half of the BCAA catabolic pathway (Figure 7A). With 262 
exception of the BCATs, enzyme expression was rarely significantly upregulated, leading to a broad net suppression 263 
across the profiled cancers (Figure 7B). Oncomine (Rhodes et al., 2004) analysis confirmed that these expression 264 
changes were consistent across multiple validated cohorts (Figure S6A). Notably, BCAA catabolic enzyme 265 
expression was also strongly associated with tumor progression in some cancers. Similar to HCCs, reduced 266 
expression correlated with tumor progression and aggressiveness in cancers of the colon & rectum, stomach, kidney, 267 
and adrenal cortex (Figure 7C). Moreover, the expression levels of numerous BCAA catabolic enzymes could be 268 
used to robustly predict patient survival among these cancers (Figure S6B). 269 
 Recent reports have identified enhanced expression of the BCAT enzymes, which catalyze the reversible 270 
transamination step, in some cancers (Hattori et al., 2017; Mayers et al., 2016; Raffel et al., 2017). However, 271 
opposing metabolic fluxes were observed and conflicting mechanisms were proposed. In some non-small cell lung 272 
cancers (NSCLC) and acute myeloid leukemias (AML), enhanced uptake of BCAAs and conversion to α-ketoacids 273 
is thought to provide substrates for nucleotide synthesis and maintain α-ketoglutarate homeostasis (Mayers et al., 274 
2016; Raffel et al., 2017). In contrast, chronic myeloid leukemia (CML) displays enhanced production of BCAAs 275 
from α-ketoacids, which promotes mTOR activation (Hattori et al., 2017). Why enhanced expression of the same 276 
enzyme (BCAT1) leads to opposing net metabolic fluxes in these cancers has not been clarified. As noted, we 277 
examined the expression of BCAT1 and BCAT2, but found no consistent changes across the human HCC samples, 278 
liver-derived cell lines, and animal tumor models (Figures S1C-E). Moreover, we observed that supplying either 279 
BCAAs or α-ketoacids was sufficient to stimulate mTORC1 (Figure S6C), suggesting that these metabolites are 280 
readily imported and interconverted. In contrast to effects observed in NSCLC and CML, inhibition of BCAT1 281 
actually enhanced the proliferation of HepG2 cells, an effect lost upon removal of BCAAs from the media (Figures 282 
S6D-F). Thus, while examination of the BCATs requires further investigation, our data suggest that the distal 283 
irreversible enzymatic steps can also influence the catabolic flux of BCAAs, and indeed may be more important for 284 
certain tissues and cancers.   285 
 286 
Low Tissue Catabolism and High Dietary Intake of BCAAs is Associated with High Overall Cancer Mortality 287 
Risk 288 
Finally, we examined how tissue catabolism and dietary intake of BCAAs may impact overall cancer mortality. In 289 
total, TCGA has transcriptionally profiled 33 cancers (i.e. including those without any/sufficient normal tissues for 290 
comparison). Therefore, we used the combined expression index of BCKDHA, ACADS, and ACADSB to screen the 291 
cancer cohorts with at least 15 verified deaths for differences in clinical outcome. Overall, approximately 60% of 292 
cancers had a modest to strong bifurcation in patient survival, with high expression of these three genes associated 293 
with better outcome (Figures 7D and S7A). The remaining cancers had minimal difference in survival (Figure S7A). 294 
Thus, when collectively analyzed them as a pan-cancer cohort, patients with higher tumor expression of BCKDHA, 295 
ACADS, and ACADSB lived significantly longer (1849 days versus 732 days at 70% survival; Figure S7B).  296 
 To determine if dietary intake of BCAAs correlated with cancer mortality in humans, we analyzed the 297 
National Health and Nutrition Examination Survey (NHANES) III dataset with linked mortality data. In this cohort, 298 
we calculated that the BCAAs comprised 17.3% of total protein intake. Given dietary recommendations for protein 299 
at 10-35% of total kcal, we set the threshold for low BCAA intake at 1.73% (10% protein/total kcal x 17.3% 300 
BCAA/total protein kcal). Few individuals consumed very high protein diets (>35% of total kcal), so we set the 301 
threshold for high BCAA intake at 3.89%, which is at the median of recommended protein intake (22.5% 302 
protein/total kcal x 17.3%BCAA/total protein kcal). Overall, individuals 50-66 years old in the highest tertile of 303 
BCAA intake had a 200% increased risk of death from cancer relative to the lowest tertile, even when adjusting for 304 
known confounders, as well as percent kilocalories from fat, carbohydrate, and non-BCAA protein intake (Figures 305 
7E and S7C). When evaluated as continuous substitutive variables, isocalorically replacing 3% of energy from 306 
BCAAs with either carbohydrate or fat decreased cancer mortality risk by more than 50% (Figure 7F). While the 307 
effect of substituting BCAAs with non-BCAA protein could not be accurately evaluated due to high collinearity 308 
between the variables (r=0.975), non-BCAA protein intake was associated with only a modest change in cancer 309 
mortality risk (Figure S7D). These associations were not significant in more elderly populations, likely because they 310 
have higher basal protein requirements (Figures S7E-G).  311 
 312 
Discussion 313 
In summary, utilization of comprehensive transcriptomic and metabolomic analyses of primary HCCs and animal 314 
liver cancer models identified an important role for BCAA catabolism in tumor development, progression and 315 
growth (Figure 7G). The changes in both enzyme expression and metabolite concentration were consistent in liver 316 
cancer across etiological backgrounds from multiple cohorts, positively selected for during disease progression, and 317 
significantly associated with patient survival. Animal tumor models and cancer cell lines notably had analogous 318 
transcriptomic and metabolomic profiles, while regenerating tissues explicitly did not show similar changes. Taken 319 
together, the data provide assurance that the observed suppression of BCAA catabolism is not simply related to 320 
generic proliferation, but rather, has some degree of specificity to carcinogenesis. More broadly, combining multi-321 
omic data from the same set of samples helped reveal changes in metabolic fluxes that would be difficult to identify 322 
or explain with the data from just one platform, and thus, this experimental approach could potentially provide 323 
significant insights when used to analyze other forms of cancer. Of note, the transcriptomic and metabolomic 324 
analyses demonstrated that numerous additional metabolites and metabolic pathways were consistently altered in 325 
tumors that could be targeted for additional beneficial effects (Figures 1, 2, S1, and S2). Some of these, such as 326 
serine/glycine (Maddocks et al., 2017), and proline (Loayza-Puch et al., 2016) metabolism have been characterized 327 
in other cancers and warrant further investigation in liver cancer. 328 
 Reduced serum BCAAs have been observed in patients with liver cirrhosis and related disease states 329 
(Marchesini et al., 2003). We also frequently observed this phenomenon in the animal tumor models analyzed (data 330 
not shown). Thus far, it has been assumed that reduced serum BCAAs is a sign of inadequate BCAA intake and/or 331 
enhanced BCAA catabolism, leading to recommendations for BCAA supplementation therapy (Marchesini et al., 332 
2005). However, the data presented here suggest low serum BCAAs may in part be a consequence of BCAA 333 
accumulation in the liver. In fact, previous reports have observed that liver BCKDH activity is reduced in patients 334 
with cirrhosis (Taniguchi et al., 1996). Although the acute beneficial effect of BCAA supplementation on hepatic 335 
encephalopathy and clinical parameters has been reported, these results are not consistent, and providing non-BCAA 336 
caloric supplements may be just as effective (Charlton, 2006). Considering the data presented here, and the 337 
increased risk of liver cancer in cirrhotic and liver disease patients, a careful re-evaluation of this practice should be 338 
undertaken. Moreover, BCAA dietary supplements are commercially available and contain 2-8 grams of BCAAs per 339 
serving, an additional 100-400% above RDA/AMDR (recommended daily allowance/acceptable macronutrient 340 
distribution range) levels. While likely safe for use in individuals with normal liver function, clinicians should be 341 
aware if their patients, particularly those with liver diseases, are consuming these products.  342 
 Obesity and diabetes are associated with an increased risk of incidence and mortality for a range of cancers 343 
(AICR, 2018). This association is particularly strong for liver cancers (Chen et al., 2008), yet the mechanisms 344 
involved remain a matter of debate. Previous data have shown that the local expression of tumor-promoting pro-345 
inflammatory cytokines such as TNFα and IL-6 are enhanced after genetic- or diet-induced obesity (Park et al., 346 
2010). While our data are generally consistent with these reports, we have frequently found that the change in 347 
expression after HFD feeding to be somewhat minor relative to the increase in pre-tumor tissues versus the normal 348 
liver (Figure S5E). As previously reported (Newgard et al., 2009), we observed that a HFD also enhances tissue 349 
BCAA accumulation, presumably due to fatty acids competing with BCAAs for access to shared catabolic enzymes 350 
(Newgard, 2012). Moreover, multiple groups have reported altered BCAA metabolism in the setting of obesity and 351 
diabetes (Newgard et al., 2009; Pedersen et al., 2016; Wang et al., 2011). Thus, the data presented here offer an 352 
additional or alternative mechanism by which these metabolic diseases influence the development and progression 353 
of certain cancers.  354 
 The cellular uptake of BCAAs is largely attributed to the Large-neutral Amino Acid Transporters (LATs) 355 
(Wang and Holst, 2015). While there were some changes in expression across the animal tumor models, none of 356 
them met our criteria of being upregulated in tumor models but not regenerating tissues (Figure S7H). Moreover, we 357 
observed minimal changes in human HCCs relative to adjacent normal liver tissues (Figure S7H), and high tumor 358 
expression of the LAT transporters was not associated with significantly worse patient survival (Figure S7I). These 359 
transporters also import a wide array of neutral amino acids, and we did not observe a consistent accumulation of 360 
other amino acids in tumors. Thus, given a consistent rate of amino acid import, the data suggest that BCAAs are 361 
specifically diverted from catabolism due to changes in catabolic enzyme expression. We acknowledge that multiple 362 
factors likely influence the intracellular concentration of BCAAs, but our data point towards the suppression of 363 
irreversible catabolic enzymes (most notably BCKDHA, ACADS, and ACADSB) as playing a critical role in liver 364 
and potentially other cancers. 365 
 While BCAAs are believed to have pleiotropic effects through defined (Jang et al., 2016; Mayers et al., 2016) 366 
and unknown (Taya et al., 2016) mechanisms, stimulation of mTORC1 is the most potent and extensively-367 
characterized (Laplante and Sabatini, 2012). Although growth factor signaling to mTORC1 is critical, it is not 368 
sufficient for activation. Equally important is the nutrient sufficiency signaling to mTORC1, and removal of either 369 
input renders mTORC1 inactive (Sancak et al., 2008). Recent comprehensive genetic analyses have revealed that 370 
numerous cancers harbor mutations that chronically activate the growth factor arm of mTORC1 (Sanchez-Vega et 371 
al., 2018). Interestingly, chronic activation of mTORC1’s growth factor arm plays a particularly central role in the 372 
pathogenesis of the cancers displaying the most overt suppression of BCAA catabolism (Figures 7, S6, and S7) 373 
(Cancer Genome Atlas, 2012; Cancer Genome Atlas Research, 2013, 2014; Cancer Genome Atlas Research et al., 374 
2016; Zheng et al., 2016). Moreover, like in liver cancer, chronic activation of growth factor signaling to mTORC1 375 
(through the deletion of TSC1 or TSC2) enhances tumorigenesis in cancer models of the kidney (Kobayashi et al., 376 
1999), intestine (Faller et al., 2015), mesothelium (Guo et al., 2014) and other tissues (Hsieh et al., 2012; Liang et al., 377 
2010). Yet it has remained unclear if and how tumors ensure chronic activation of the nutrient sensing arm of 378 
mTORC1. The data presented here suggest that tumors may manipulate specific nutrients to achieve this. This 379 
mechanism would likely be more favorable for cancer cell growth, as it would provide enhanced pro-growth 380 
signaling under most conditions while still allowing for pathway inhibition in cases of extreme starvation.   381 
 mTOR plays an important, albeit complex, role in tissue homeostasis and tumorigenesis. In liver cancer, 382 
targeting the mTOR pathway with first- or second-generation inhibitors has thus far led to tepid and mixed results 383 
(Matter et al., 2014). Although treatments have successfully retarded tumor development and growth in selected 384 
animal models and clinical trials (Matter et al., 2014; Menon et al., 2012), broad blockage of the mTOR pathway 385 
can also enhance tumorigenesis through the death of normal and regenerating hepatocytes (Umemura et al., 2014). It 386 
has also been reported that mTORC1 inhibition can be beneficial to K-ras-driven pancreatic cancers under certain 387 
conditions (Palm et al., 2015). Though subsequent work has shown this is due to restoration of the balance between 388 
amino acid supply and protein synthesis through the stimulation of macropinocytosis and lysosomal degradation of 389 
extracellular proteins (Nofal et al., 2017). These behaviors have been attributed to mutant K-ras, and while nearly all 390 
pancreatic cancers have K-ras mutations, only 1% of HCCs harbor these (Ally et al., 2017). In addition, pancreatic 391 
cancers have enhanced expression of autophagy/lysosomal genes (Perera et al., 2015), but we found no similar 392 
changes in hepatic, gastrointestinal, or renal cancers (data not shown), which have the most overt changes in BCAA 393 
catabolism. We also repeatedly found no beneficial effect of mTOR inhibition or extracellular protein 394 
supplementation for the liver cancer models analyzed, either in nutrient complete or starved conditions. Thus, 395 
cancers of various tissues, particularly those driven by alternate oncogenes, likely handle BCAA intake/catabolism 396 
and chronic mTORC1 activation differently. Nonetheless, identification of the mechanisms that specifically regulate 397 
mTORC1 in cancer cells may provide targeted and more effective therapeutic results.  398 
 Overall, we find that BCAA catabolism is a metabolic pathway potently and robustly altered in certain 399 
cancers. Not only can this pathway be examined and utilized for its diagnostic and prognostic value, but dietary and 400 
pharmacologic interventions may effectively modulate tumor development and growth while minimally affecting 401 
normal and regenerating tissues. In addition, the data presented here and elsewhere (Hattori et al., 2017) raise the 402 
intriguing possibility that changes in tumor metabolism may not strictly be used for anabolic purposes, but can also 403 
be used to influence established oncogenic signaling pathways. 404 
 405 
Limitations of Study 406 
 The methods and models used in our study are not without limitations. Current metabolic analytic tools treat 407 
metabolic pathways discreetly, whereas in vivo, these pathways are interconnected and constantly in flux. The 408 
development of more comprehensive analytic tools will help address the role of individual enzymes in regulating 409 
flux within a pathway, as well as the interplay of multiple pathways and their relative contribution to observed 410 
phenotypic changes. Moreover, flux studies involving labeled BCAAs and/or related metabolites will be needed to 411 
confirm the metabolic changes suggested by the transcriptomic and metabolomic analyses. Repeating in vitro studies 412 
in more complex and physiologically relevant models (such as primary hepatocytes and organoids) and in vivo 413 
studies in alternate, genetic-based models will also help examine the robustness of the phenotypes observed. 414 
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 598 
Main Figures Legends 599 
Figure 1. BCAA Catabolism Is Suppressed During Hepatocellular Carcinoma Development and Progression 600 
(A) Comparison of gene expression changes in hepatocellular carcinomas (HCCs) relative to adjacent nontumor 601 
liver tissues, collected at Singapore General Hospital (SGH) or characterized by the cancer genome atlas (TCGA-602 
LIHC).  603 
(B) 1405 genes were similarly altered in both cohorts with high significance (p<1x10-8).  604 
(C) KEGG pathway analysis of the 1405 gene set.  605 
(D) Summary of branched-chain amino acid (BCAA) catabolic enzyme transcript levels across HCCs and nontumor 606 
liver tissues of both cohorts.  607 
(E) Immunoblots of selected BCAA catabolic enzymes from paired HCCs and nontumor liver tissues from patients 608 
of the SGH cohort. 609 
(F) Representative immunohistochemical micrographs from nontumor liver tissue and HCC biopsies, as profiled by 610 
The Human Protein Atlas. 611 
(G) Ex vivo tissue BCKDH complex activity from paired HCCs and nontumor liver tissues from patients of the SGH 612 
cohort (n=6 per group).  613 
(H) Summary of all significantly different metabolites from targeted metabolomics analyses from paired HCCs and 614 
nontumor liver tissues from patients of the SGH cohort (n=7 per group).  615 
(I) Summary of BCAA catabolic enzyme transcript levels in HCCs from the SGH and TCGA cohorts, sorted by 616 
stage, grade, metastasis, vascular invasion, and local invasion.  617 
(J) Kaplan-Meier survival estimate curves for patients ranked by a combined index of tumor BCKDHA, ACADS, 618 
and ACADSB expression. P-values for log-rank test and cox proportional hazard ratios (HR, with 95% percent 619 
confidence intervals) adjusted for age, sex, tumor stage and grade, and radiation, prescription and additional 620 
therapies shown.  621 
*P<0.05, compared to respective controls. Data are shown as mean ± s.e.m. 622 
See also Figure S1. 623 
 624 
Figure 2. Loss of BCAA Catabolism Occurs in Liver Tumors, but Not Regenerating Liver Tissues  625 
(A-E) Transcriptomic and metabolomic characterization of animal tumor models. DEN-induced tumors are 626 
compared to DEN nontumor tissue, and orthotopic tumors (Morris Hepatoma) and regenerating liver tissue after 627 
partial hepatectomy are compared to normal liver tissue. (A) Summary of significant, differentially-expressed genes. 628 
(B) KEGG pathway analysis of the 976 genes differentially expressed in tumors but not regenerating tissues. (C) 629 
Summary of BCAA catabolic enzyme transcript levels across normal, tumor, and regenerating tissues. (D) 630 
Quantification of tissue amino acid content, normalized to respective controls. nd=not detected. (E) Quantification 631 
of tissue acylcarnitine content, normalized to respective controls. Only acylcarnitines that trended in the same 632 
direction in both tumor models are shown. †P<0.05, in 1 of 2 tumor models, ‡P<0.05 in both tumor models, 633 
compared to respective controls, while not significantly different in regenerating tissue. 634 
(F) Immunoblots of selected BCAA catabolic enzymes in normal, tumor, and regenerating liver tissues.  635 
(G) Quantification of phospho:total BCKDHA ratio, and corresponding ex vivo tissue BCKDH complex enzymatic 636 
activity.  637 
(H) Immunoblots of mitochondrial fractions from normal, tumor, and regenerating liver tissues. 638 
(I) Schematic of magnetic resonance spectroscopy (MRS)-based in vivo BCKDH complex activity assay. 639 
Hyperpolarized [1-C13] α-ketoisocaproate was injected by tail vein, and enzyme activity was assessed by detection 640 
of labeled bicarbonate in the liver in live, anesthetized animals.  641 
(J) Representative liver MRS spectra after intravenous injection of hyperpolarized [1-C13]α-ketoisocaproate (KIC). 642 
Baselines are shifted to display the difference in bicarbonate peak. Quantification of relative bicarbonate levels over 643 
a 30 second interval inset.  644 
*P<0.05, compared to respective controls; Data are shown as mean ± s.e.m. 645 
See also Figure S2. 646 
 647 
Figure 3. Loss of BCAA Catabolic Enzyme Expression Is Associated with Changes in Copy Number 648 
Variation and Transcription Factor Expression/Activity 649 
(A) Summary of BCAA catabolic enzyme transcript levels in nontumor liver tissues, and tumors with or without 650 
CNV loss of indicated gene. 651 
(B) Distribution of CNV losses of the BCAA catabolic enzymes in the TCGA-LIHC cohort, sorted by unsupervised 652 
hierarchical clustering.  653 
(C) Summary of BCAA catabolic enzyme expression in nontumorigenic (HepG2) and tumorigenic (remaining) 654 
hepatoma/HCC-derived cell lines.  655 
(D) Immunoblots of selected BCAA catabolic enzymes across the cell line panel.  (E) RT-PCR analysis of BCAA 656 
catabolic enzymes from HepG2 cells treated with the PPARα antagonist GW6471 for 48 hours.  657 
*P<0.05, compared to respective controls. Data are shown as mean ± s.e.m. 658 
See also Figure S3. 659 
 660 
Figure 4. BCAA Catabolism Regulates mTORC1 Activity and in vitro Cell Proliferation 661 
(A) Immunoblots of mTORC1 downstream effectors (S6K and S6) and their activation states (p-S6KThr389 and p-662 
S6Ser235/236) in paired HCCs and nontumor liver tissues from patients of the SGH cohort. 663 
(B) Real-time proliferation curves, immunoblots detailing knockdown efficiency (BCKDHA) and mTORC1 664 
activity, and intracellular BCAA content of AML12 cells expressing a tet-inducible BCKDHA shRNA in the 665 
absence or presence of doxycycline and/or the mTOR inhibitors rapamycin (0.05nM) or Torin 1 (0.5nM). 666 
(C) Real-time proliferation curves and immunoblots of Hep3B cells grown in media with reduced levels of BCAAs.  667 
(D) Real-time proliferation curves and immunoblots of Hep3B cells overexpressing Flag-tagged BCKDHA, 668 
ACADS, or ACADSB.  669 
(E) Real-time proliferation curves and immunoblots of control and CRISPR-Cas9-mediated BCKDK null Hep3B 670 
clones.  671 
(F) Real-time proliferation curves of Hep3B cells treated with the BCKDK inhibitor BT2, and immunoblots after 2 672 
hours of BT2 treatment.  673 
(G) Calculation of proliferation rates (number of divisions per day) for HCC cell lines treated with BT2.  674 
(H) Colocalization of mTOR and the lysosomal marker LAMP2 in Hep3B cells grown in nutrient sufficient 675 
(control) media, after 1 hour of amino acid withdrawal, or after 2 hours of BT2 treatment (150µM). Quantification 676 
displays Manders overlap of 20 random cells.  677 
(I) Immunoblots of 293T cells expressing control vectors (pLOC or Flag-Raptor) or constitutively active 678 
components of mTORC1-related nutrient sensing complexes (HA-RagBS75L/HA-RagCQ99L or Flag-Raptor-Rheb15) 679 
treated with vehicle or indicated concentration of BT2 for 2 hours. 680 
(J) Immunoblots of 293T cells with GFP or Sestrin 1, 2, and 3 knockdown, treated with vehicle or indicated 681 
concentration of BT2 for 2 hours.  682 
*P<0.05, compared to respective controls. Data are shown as mean ± s.e.m. 683 
See also Figure S4. 684 
 685 
Figure 5. High Dietary BCAA Intake Enhances Tumor Development and Growth in vivo  686 
(A-C) Analysis of mice 5 months after DEN injection, fed either a low fat diet (LFD, 10% kcal from fat) or high fat 687 
diet (HFD, 45% kcal from fat) with normal or high (+150%, +BCAA) levels of BCAAs. (A) Representative livers 688 
from DEN-injected mice. (B) Quantification of tumor incidence and tumor sizes of DEN-injected mice. (C) Liver 689 
masses of DEN-injected and control uninjected mice, normalized to total body weight. 690 
(D-M) Analysis of mice 8 months after DEN injection fed indicated diets. (D) Representative livers from DEN-691 
injected mice. (E) Quantification of tumor incidence of DEN-injected groups (F) Quantification of the number of 692 
tumors (≥3mm) and size of the largest tumor per mouse from DEN-injected mice. (G) Liver masses of DEN-693 
injected and uninjected mice, normalized to total body weight. (H) RT-PCR analysis of BCAA catabolic enzymes of 694 
normal liver tissue (from uninjected mice), and nontumor and tumor liver tissues (from DEN-injected mice). Results 695 
normalized to normal liver tissue of LFD-fed mice. Statistical analyses summarized in Figure S5A. (I) 696 
Quantification of BCAA content in nontumor liver tissues of DEN-injected mice, and its correlation with tumor 697 
multiplicity. (J) Quantification of BCAA content in tumors of DEN-injected mice. (K) Representative histological 698 
and immunohistochemical analyses of livers from DEN-injected mice. (L) Immunoblots of nontumor liver tissues 699 
from DEN-injected mice and quantification of phospho:total p70S6K ratios.   700 
*P<0.05 vs. LFD, §P<0.05 vs HFD. Data are shown as mean ± s.e.m. 701 
See also Figure S5. 702 
 703 
Figure 6. Enhancing BCAA Catabolism or Restricting Dietary BCAAs Limits Tumor Burden in vivo  704 
(A,B) Analysis of mice 8 months after DEN injection, fed either LFD+BCAA or HFD+BCAA diets without/with 705 
0.02% BT2. (A) Representative livers. (B) Quantification of the number of tumors (≥3mm) and size of the largest 706 
tumor per mouse.  707 
(C) Kaplan-Meier survival curves of DEN-injected mice fed LFDs with low (-50%, -lowBCAA), standard, or high 708 
(+150%, +BCAA) levels of BCAAs. 709 
(D-J) Analysis of mice 12 months after DEN injection, fed indicated diets. (D) Representative livers. (E) Average 710 
tumor sizes. (F) Quantification of BCAA content in nontumor liver tissues. (G) Representative histological and 711 
immunohistochemical analyses of livers from DEN-injected mice. (H) Liver masses (normalized to total body 712 
weight) and nonliver lean body mass of DEN-injected and uninjected mice. (I) RT-PCR analysis of BCAA catabolic 713 
enzymes of normal liver tissue (from uninjected mice), and nontumor and tumor liver tissues (from DEN-injected 714 
mice). Results normalized to normal liver tissue of LFD-fed mice. Statistical analyses summarized in Figure S5H. 715 
(J) Average tumor sizes of DEN-injected mice, based on % kcal from BCAAs and % kcal from total protein. Non-716 
BCAA amino acids were adjusted proportionally to match the total protein content of low- or high-BCAA diets. 717 
*P<0.05 vs. LFD, †P<0.05 vs LFD+BCAA, ‡P<0.05 vs HFD+BCAA. Data are shown as mean ± s.e.m. 718 
See also Figure S5. 719 
 720 
Figure 7. The Overall Impact of BCAA Tissue Catabolism and Dietary Intake on Cancer Development, 721 
Progression, and Mortality  722 
(A,B) Summary of BCAA catabolic enzyme transcript levels for all cancers profiled by The Cancer Genome Atlas 723 
(TCGA) with at least 5 solid normal tissue samples. (A) Heatmap displaying expression in normal and tumor tissues 724 
of individual cancers. Cancers are arranged from those with the greatest number of enzymes suppressed (top) to the 725 
least (bottom) and genes are arranged from those suppressed in the greatest number of cancers (left) to the least 726 
(right). (B) Summary of the BCAA catabolic pathway indicating net expression changes across all tumors. 727 
(C) Summary of BCAA catabolic enzyme transcript levels in tumors of the TCGA datasets COADREAD, STAD, 728 
ACC, KIRC, KIRP, and KICH, sorted by stage, grade, local invasion, lymph node invasion, and metastasis. 729 
(D) Quantification of cox proportional hazard ratios (95% confidence intervals), significance (log-rank p-value), 730 
robustness, and difference in days of estimated survival for patients across all cancers profiled by TCGA with at 731 
least 15 verified deaths with low tumor expression of ACADS, ACADSB, and BCKDHA. 732 
(E,F) Analysis of individuals 50-66 years-old in the NHANES III dataset. (E) Hazard ratios (HR, with 95% 733 
confidence intervals) based on BCAA intake, 1adjusted for age, sex, race, total kcal, usual dietary intake, diet 734 
change, physical activity, intentional weight loss, waist circumference, smoking, education, and prior diagnosis of 735 
cancer, diabetes and cardiovascular disease, 2additionally adjusted for % kcal from other macronutrients. (F) 736 
Substitution analysis comparing change in risk when replacing BCAAs with carbohydrate or fat, with the same 737 
adjustments as HR2 except total kcal and % kcal from non-BCAA protein. Data are presented as hazard ratio (solid 738 
line) with 95% confidence interval (shaded area). 739 
(G) Summary of BCAA catabolism in normal, regenerating, and cancerous liver tissues. 740 
See also Figure S6 and S7. 741 
 742 
STAR Methods 743 
CONTACT FOR REAGENT AND RESOURCE SHARING 744 
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead 745 
Contact, Weiping Han (weiping_han@sbic.a-star.edu.sg). 746 
 747 
EXPERIMENTAL MODELS AND SUBJECT DETAILS 748 
Human Subjects and Data  749 
The Singapore General Hospital cohort includes primary tumors and adjacent nontumor tissues that were surgically 750 
removed at the National Cancer Centre Singapore between 2008 and 2011. All samples used for analysis were 751 
obtained in the context of clinically indicated surgery with informed consent from the patient, in accordance with the 752 
Declaration of Helsinki and using protocols approved by the SingHealth Institutional Review Board at the National 753 
Cancer Center Singapore. Resected tissues were snap frozen, sectioned, and analyzed by pathologists to score the 754 
tumors and identify neoplastic and nonneoplastic regions. RNA-Seq raw count, copy number variation, and 755 
mutational data, along with associated clinical information from the TCGA cohorts were downloaded from The 756 
Cancer Genome Atlas (cancergenome.nih.gov) and/or UCSC Cancer Genomics Browser (genome-cancer.ucsc.edu). 757 
Oncomine data were examined with the filters data type: mRNA, gene rank threshold: all; fold change threshold: 758 
1.5; p-value threshold: 0.05 (oncomine.org). Biopsy immunohistochemical micrographs were downloaded from The 759 
Human Protein Atlas (proteinatlas.org). Dietary and mortality data for the NHANES III cohort were downloaded 760 
from the Centers for Disease Control and Prevention (cdc.gov/nchs/nhanes). 761 
 762 
Animal Studies  763 
All animal studies were approved by the Institutional Animal Care and Use Committee at A*STAR. Animals were 764 
fed ad libitum and maintained in a specific pathogen free facility with constant ambient temperature and a 12-hour 765 
light cycle. C57BL/6 mice for breeding were obtained from Biological Resource Center, A*STAR. 15 day-old pups 766 
were injected i.p. with a single 50 mg/kg dose of Diethylnitrosamine (DEN). DEN nontumor and tumor tissues were 767 
harvested from injected mice, while normal liver tissues were collected from age-matched mice without DEN 768 
injection. ACI rats were obtained from Harlan (Dublin, VA) and used in all rat studies. For the regenerating liver 769 
model, 10-12 week-old rats were anesthetized and two-thirds of the liver was removed as previously described 770 
(Michalopoulos and DeFrances, 1997). Liver tissue was harvested 24 hours later, at a time when hepatocyte 771 
proliferation is at its highest (Michalopoulos and DeFrances, 1997). For the Morris Hepatoma model, 10 week-old 772 
rats were anesthetized, 1 million MH3924a cells were injected directly into the liver, and tumors were harvested two 773 
weeks later. Control rat liver was harvested from age-matched rats. For rat DEN model, DEN was given to 10 week-774 
old rats via drinking water containing 100 mg/L DEN for up to 4 months, and control rat livers from age-matched 775 
rats were analyzed. During sacrifice, animals were anesthetized and blood was collected by cardiac puncture and 776 
death was confirmed by cervical dislocation. Livers were resected, measured by electronic calipers and snap frozen 777 
in liquid nitrogen. For mice on special diets, animals were randomly assigned to experimental groups upon weaning. 778 
Sample sizes were estimated based on prior experience with the DEN model with a power analysis, including a 779 
power level of 80% and confidence interval of 95%. Chow diets were obtained from Altromin (#1320, modified), 780 
including those with added 0.2% BT2. Custom purified diets were purchased from Research Diets, Inc. (New 781 
Brunswick, NJ) and their composition is summarized in Table S1. Diets were given to animals at 12 weeks of age 782 
until termination of the study. Body weights were measured weekly and prior to sacrifice lean and fat mass were 783 
measured by an EchoMRI Body Composition Analyzer. After sacrifice, tissues were assigned random ID numbers 784 
and analyses were performed blinded to experimental group information. 785 
 786 
Cell Culture Studies  787 
Cell lines were obtained from ATCC (AML12, HepG2, Hep3B, SNU182, SNU387, SNU398, and SNU449), the 788 
Japanese Collection of Research Bioresources (Huh7), and the German Cancer Research Center Tumor Collection 789 
(Morris Hepatoma 3924a) and not further verified. Only cell stocks that had tested negative for mycoplasma within 790 
the prior 9 months were used. HepG2 cells were maintained in EMEM, and remaining cell lines were maintained in 791 
RPMI 1640, with 10% FBS and 1% Pen Strep (Gibco), and grown in a 37ºC humidified incubator with 5% CO2. 792 
Real-time cell growth measurements were taken on an xCELLigence RTCA SP (Acea) at 15-minute intervals. For 793 
studies involving BCAA-reduced/free or AA-free media, amino acid free RPMI (USBiological) was prepared, and 794 
supplemented with purified amino acids (Sigma) and/or 10% Dialyzed FBS and 1% Pen Strep (Gibco). Indicated 795 
cultures were treated with an additional 3% Albumin (Sigma), 20% FBS (Gibco), Gabapentin (Sigma), or purified 796 
amino acids (Sigma) dissolved in media. For transcription factor antagonist studies, cells were seeded in 10cm 797 
dishes and treated with GW6471 (Sigma) or vehicle (DMSO) for 48 hours when cells were approximately 80% 798 
confluent. For compound treatment growth curves, cells were seeded in quadruplicate at 1,250, 2,500 or 5,000 cells 799 
per well and normalized 12 hours later (time 0 hours), immediately prior to changing half of the media to add 800 
compounds or vehicle. Proliferation rates were calculated over a 48-hour period beginning 2 hours after addition of 801 
BT2 (3,6-dichlorobenzo[b]thiophene-2-carboxylic acid; Matrix Scientific), Rapamycin (Tocris), Torin 1 (Tocris), or 802 
vehicle (DMSO). For immunoblots, cells were seeded in 10 cm dishes and allowed to grow for at least 24 hours. At 803 
approximately 80% confluence the media was changed to include indicated amounts of compound or vehicle and 804 
whole cell lysates were harvested 2 hours later. For inducible BCKDHA knockdowns, interfering RNA for target 805 
sequences were inserted into the Tet-pLKO-puro vector (Wiederschain et al., 2009) (Addgene plasmid #21915; 806 
BCKDHA shRNA1: CCGGTCCTTCTACATGACCAACTATCTC 807 
GAGATAGTTGGTCATGTAGAAGGATTTTTG; shRNA2: CCGGGCAGTCACGAAAGAAGGTCATCTCG 808 
AGATGACCTTCTTTCGTGACTGCTTTTTG). The resulting constructs, along with lentiviral packaging vectors, 809 
were transfected into HEK293T cells with Lipofectamine 2000 (Invitrogen) following manufacturer’s protocol. 810 
Supernatants containing lentivirus were collected 24 hours later, passed through 0.2µm filters, and added to recipient 811 
cell lines for 24 hours along with 8µg/mL polybrene (Sigma). Cells were then incubated in selection media (1-812 
3µg/mL puromycin, depending on cell line sensitivity) for 5-7 days. For growth curves, cells were maintained in 813 
250µg/mL doxycycline for 5 days, then seeded into wells with (+Dox) or without (-Dox) doxycycline in 814 
quadruplicate at 625, 1,250, 2,500 or 5,000 cells per well. Wells were normalized 12 hours later (Day 0) and allowed 815 
to grow without media change or addition of more doxycycline. Proliferation rates were calculated over a 7-day 816 
period (Day 0 to Day 7). For immunoblots, cells were seeded in 10 or 15 cm dishes, split or received media change 817 
every 3-4 days to maintain a doxycycline, Rapamycin, and Torin 1 concentrations, and harvested after 10 days. For 818 
CRISPR-Cas9-induced mutagenesis, previously published methods were followed (Sanjana et al., 2014). Briefly, 819 
sgRNAs were computationally identified (http://www.genome-engineering.org/crispr) and inserted into the 820 
lentiCRISPRv2 vector (Addgene plasmid #52961; BCKDK target the sequence GTCGGCCATCGACGCGGCAG). 821 
Lentivirus was produced as detailed above, and Hep3B cells were transduced and underwent with 1µg/mL 822 
puromycin selection for 7 days. Single-cell colonies were generated and 80 clones were examined for mutations by 823 
sequencing 15-20 PCR products of the target region. LentiCRISPRv2 empty vector-transduced Hep3B cells were 824 
used as controls, which behaved similarly to parental Hep3B cells and non-frameshift BCKDK mutant Hep3B 825 
clones. For growth curves, 1250 cells from each clone were plated in quadruplicate, normalized 6 hours later, and 826 
allowed to grow for 5 days. For immunoblots, cells were seeded into 10cm or 15cm dishes and harvested 10 days 827 
later as whole cell lysates, or as purified mitochondrial fractions using an isolation kit (Thermo Fisher). For PPARα 828 
knockdowns, target sequences embedded in the lentiviral SMARTvector were obtained from Dharmacon (PPARα 829 
shRNA1: AAATGGGTTTATAACTCGT, shRNA2: TCATAAGCTAGCACCCGTG; Nontargeting shRNA: Clone 830 
ID VSC11716). Lentivirus was produced as detailed above, and HepG2 cells were transduced and underwent with 831 
1µg/mL puromycin selection for 7 days. Cells were seeded in 10cm dishes and harvested 48 hours later, when the 832 
cells were approximately 80% confluent. For ACADS, ACADSB, and BCKDHA overexpression studies, full-length 833 
protein-coding regions (CDS) were obtained from Dharmacon (BCKDHA clone ID: 4065221; ACADSB clone ID: 834 
PLOHS_100070589) or as a kind gift (ACADS from Dr. Gerard Vockley) and subcloned into a pCMV vector to add 835 
a FLAG-tag to the C terminus. The FLAG-tagged CDS was then subcloned into the pLOC lentriviral vector.  836 
Lentivirus was produced as detailed above, and Hep3B cells were transduced and underwent with 1µg/mL 837 
puromycin selection for 7 days. For Sestrin 1/2/3 knockdowns, interfering RNA for target sequences were inserted 838 
into the pLKO-puro vector (Moffat et al., 2006) (Addgene plasmid # 10878; Sestrin1 shRNA: 839 
TCGTCACTACATTGGAATAAT; Sestrin2 shRNA: GCGGAACCTCAAGGTCTATAT; Sestrin3 shRNA: 840 
GCCTTAATGGAAAGGATGAAA). Lentivirus was produced as detailed above, and 293T cells were transduced 841 
and underwent with 1µg/mL puromycin selection for 7 days. Knockdowns were confirmed by RT-PCR, with all 3 842 
Sestrins displaying a >90% reduction in mRNA (Chantranupong et al., 2014). RagBS75L, HA-RagCQ99L, Flag-Raptor 843 
and Flag-Raptor-Rheb15 constructs were a gift from David Sabatini via Addgene (plasmid numbers 19303, 19305, 844 
26633, and 26634), and were transfected into HEK-293T cells with Lipofectamine 2000, following manufacturer’s 845 
protocol. For all studies, results shown are one of at least three independent experiments. 846 
 847 
METHODS DETAIL 848 
Gene Expression Analyses  849 
RNA was extracted using Trizol (Life Technologies) and/or purified on RNAeasy columns (Qiagen), then analyzed 850 
for purity using RNA pico chips run on an Agilent 2100 bioanalyzer. Only samples with a RIN > 7 and 28s:18s ratio 851 
>1.0 were used in analysis. For the Singapore General Hospital cohort, gene expression was assessed using the 852 
HumanHT-12 v3 microarray chip (Illumina) and probe intensities were analyzed using the GenomeStudio software. 853 
For TCGA cohorts, raw counts were analyzed with the DESeq2 package in R. Mouse and rat samples were 854 
sequenced by Beijing Genomics Institute (BGI, Hong Kong) using the paired-end sequencing method (91 bp) with 855 
approximately 40 million reads per sample. For all cohorts, gene lists were analyzed using DAVID 856 
(david.ncifcrf.gov) and Ingenuity Pathway Analysis (Qiagen), and heat maps were generated with GenePattern 857 
(broadinstitute.org/cancer/software/genepattern). The survMisc package in R and Cutoff Finder 858 
(molpath.charite.de/cutoff) were used to identify appropriate cutoff values for splitting patients into high and low 859 
expression groups. Combined expression indexes were screened, developed, and analyzed using a method similar to 860 
the Steepest Decent (Boutros et al., 2009). Kaplan-Meier survival estimate curves and associated statistics were 861 
generated with the Survival package in R. Adjustments in hazard ratios include age at initial pathologic diagnosis, 862 
gender (male/female) tumor stage (1-4), tumor grade (1-4), radiation therapy (yes/no/unspecified), pharmaceutical 863 
therapy (yes/no/unspecified), additional therapies (additional pharmaceutical therapy, additional radiation therapy, 864 
or additional surgery procedure yes/no/unspecified), and tumor subtype (colon adenocarcinoma or rectum 865 
adenocarcinoma for colorectal adenocarcinoma; adenocarcinoma diffuse type, intestinal adenocarcinoma tubular 866 
type, intestinal adenocarcinoma mucinous type, intestinal adenocarcinoma papillary type, adenocarcinoma signet 867 
ring type, adenocarcinoma not otherwise specified, or intestinal adenocarcinoma not otherwise specified for stomach 868 
adenocarcinoma). Transcription factor binding sites in the promoters (-2000 to +100) of genes were analyzed using 869 
Transfac (geneXplain). RT-PCR reactions were run on an Applied Biosystems StepOnePlus with Power SYBR 870 
Green (Life Technologies) and primers listed in Table S2.  871 
 872 
Metabolomic Analyses 873 
Amino acids were quantified by HPLC-MS/MS using purified standards (Sigma). Acylcarnitine measurements were 874 
made by flow injection tandem mass spectrometry using sample preparation methods described previously (An et al., 875 
2004).  The data were acquired using a Waters AcquityTM  UPLC system equipped with a TQ (triple quadrupole) 876 
detector and a data system controlled by MassLynx 4.1 operating system (Waters, Milford, MA). For tissue BCKDH 877 
activity assays, frozen liver samples were pulverized in liquid nitrogen, then 200 mg of tissue was homogenized in 1 878 
mL of ice cold homogenization buffer (30 mM KPi pH7.5, 3 mM EDTA, 5 mM DTT, 1 mM α-ketoisovalerate, 3% 879 
FBS, 5% Triton X-100, 1 µM Leupeptin) using a QIAGEN TissueLyser II set at a frequency of 15/s for 1 minute. 880 
Homogenized samples were centrifuged for 10 minutes at 10,000 x g and the supernatant was collected. 50 µL of 881 
supernatant was added to 300 µL of assay buffer (50 mM HEPES pH 7.5, 30 mM KPi pH7.5, 0.4 mM CoA, 3 mM 882 
NAD+, 5% FBS, 2 mM Thiamine Pyrophosphate, 2 mM MgCl2, 7.8 µM [1-14C]α-ketoisovalerate) in a polystyrene 883 
test tube containing a raised 1 M NaOH CO2 trapping system. The tubes were capped and placed in a shaking water 884 
bath set at 37°C for 30 min. Tubes were then placed on ice and the reaction mixture was acidified by injection of 885 
100 µl of 70% perchloric acid followed by shaking on an orbital shaker at room temperature for 1 hour. The 14CO2 886 
contained in the 1 M NaOH trap was counted in a liquid scintillation counter. For magnetic resonance spectroscopy 887 
studies, approximately 48 mg of [1-13C] 2-ketoisocaproic acid (Sigma #750832), doped with 15 mM trityl-radical 888 
(OXO63, GE Healthcare) and 3 µl of gadoterate meglumine (10 mM, Dotarem®, Guerbet), was hyperpolarized in a 889 
polarizer, with 60 min of microwave irradiation. The sample was subsequently dissolved in a pressurized and heated 890 
alkaline solution, containing 100 mg/L EDTA to yield a solution of 80 mM hyperpolarized sodium [1-13C]2-891 
ketoisocaproate with a polarization of 30%, T1 of 25 seconds and physiological temperature and pH. Rats were 892 
positioned in a 9.4 T horizontal bore MR scanner interfaced to an Avance III console (Bruker Biospec), and inserted 893 
into a dual-tuned (1H/13C) rat abdominal coil (20 mm diameter). Correct positioning was confirmed by the 894 
acquisition of a coronal proton FLASH image (TE/TR, 8.0/100.0 ms; matrix size, 192 x 192; FOV, 50 x 36 mm; 895 
slice thickness, 2.0 mm; excitation flip angle, 30°). A respiratory-gated shim was used to reduce the proton 896 
linewidth to approximately 230 Hz. Immediately before injection, a respiratory-gated 13C MR pulse-acquire 897 
spectroscopy sequence was initiated. 2.0-2.5 mL (0.5 mmol /kg body weight) of hyperpolarized 2-ketoisocaproate 898 
was intravenously injected over 10 s into the anesthetized rat. Thirty individual liver spectra were acquired over 1 899 
min after injection (TR, 2 s; excitation flip angle, 25°; sweep width, 8,000 Hz; acquired points, 2,048; frequency 900 
centered on the ketoisocaproate resonance). Liver 13C MR spectra were analyzed using the AMARES algorithm as 901 
implemented in the jMRUI software package. Spectra were baseline and DC offset-corrected based on the last half 902 
of acquired points. To quantify hepatic metabolism, the spectra were summed over the first 30 s upon 2-903 
ketoisocaproate arrival. Metabolite peaks corresponding to [1-13C]2-ketoisocaproate (172.6ppm) and its metabolic 904 
derivatives [1-13C]leucine (176.8ppm) and [1-13C]bicarbonate (160.8 ppm) were fitted with prior knowledge 905 
assuming a Lorentzian line shape, peak frequencies, relative phases, and linewidths. For each animal, tCarbon is 906 
defined as the sum of all these three metabolite peaks. The normalized ratios [1-13C]leucine/tCarbon and [1-907 
13C]bicarbonate/tCarbon were computed for statistical analysis.  908 
 909 
Immunoblots, Immunocytochemistry, and Immunohistochemistry  910 
Antibodies were obtained from Abcam [Acadsb (ab99951), Bckdk (ab125389 and ab151297), Ki67 (ab15580)], Cell 911 
Signaling [BCAT1 (12822), Cleaved Caspase 3 (9664), Cox IV (4844), HA-tag (3724), mTOR (2983), p-Histone 912 
H2A.X (9718), S6 (2317), p-S6 (4858), S6K (9202), p-S6K (9234)], Santa Cruz [Bckdha (sc-67200), Gapdh (sc-913 
32233), LAMP-2 (sc-18822)], Bethyl [p-Bckdha (A304-672A)], Sigma [Acads (HPA022271), Flag (F1804), 914 
Tubulin (T5168)], and Thermo Fisher [BCAT2 (PA5-21549)]. All samples for Western blot were harvested in RIPA 915 
buffer with protease inhibitors (Roche). If mitochondrial fractions were isolated, they were done so using a 916 
mitochondrial isolation kit (Thermo), following manufacturer’s protocol. Approximately 10 µg protein samples 917 
were run by SDS-PAGE, transferred to PVDF membranes using iBlot2 (Life Technologies), blocked with 5% milk 918 
and incubated with primary antibodies in 5% BSA. Membranes were then either incubated with α-mouse/rabbit-919 
HRP secondary antibodies (GE) and developed with ECL prime (GE), or incubated with α-mouse/rabbit-IRDye 920 
680RD/800CW secondary antibodies and imaged on an Odyssey CLx (LI-COR). For immunocytochemistry, cells 921 
were grown on glass coverslips in 6-well plates for at least 24 hours before indicated treatments. At time of harvest, 922 
cells were fixed with 4% paraformaldehyde, permeabilized with 0.25% Triton X-100, and blocked with Odyssey 923 
Blocking Buffer (LI-COR). Cells were then incubated in TBST + 2%BSA with primary antibodies, followed by 924 
TBST + 2%BSA with Alexa Fluor 488 or Alexa Fluor 568 secondary antibodies (Thermo). Coverslips were then 925 
mounted to glass slides with ProLong Diamond Antifade Mountant with DAPI (Life Technologies) and sealed with 926 
nail polish. Confocal images were obtained on a Nikon A1R+si confocal microscope using the same settings for all 927 
images. Images were analyzed using Nikon NIS-Elements software package. For immunohistochemistry, liver 928 
specimens were fixed with 10% neutral buffered formalin and 70% ethanol and embedded in paraffin. Sections were 929 
cut at 7 µm, deparaffinized, subjected to citrate buffer antigen retrieval, and exposed to hydrogen peroxide to quench 930 
endogenous peroxidase prior to incubation with primary antibodies. Vectastain ABC kit and ImmPACT DAB 931 
(Vector Laboratories) were used for chromagen development, then counterstained with Harris hematoxylin. Images 932 
were obtained on a Nikon Ni-E microscope and analyzed using the Nikon NIS-Elements software package. 933 
 934 
Human Dietary Analysis  935 
NHANES III (1988-1994) is a US nationally-representative population-based survey of non-institutionalized 936 
individuals over 2 years of age (cdc.gov/nchs/nhanes). The study population included 6779 non-pregnant, non-937 
lactating adults with reliable energy intake (400-7000 kcal), ages 50-90 with mortality follow-up from the date of 938 
participation (1988-1994) through December 31, 2011. Data from the structured household interview and mobile 939 
examination center (MEC) physical examination were included in the present analysis (Parekh et al., 2012). 940 
Variables deemed important in the literature were evaluated for potential confounding, and adjusted for in final 941 
analyses. Age, sex, race/ethnicity, years of education, cigarette smoking, leisure-time physical activity, dietary 942 
intake, dietary behaviors, and doctor-diagnosed medical history were self-reported. Waist circumference was 943 
measured by trained personnel to the nearest 0.1cm at the iliac crest. Dummy variables were created for smoking 944 
status (current, former, never) based on responses to the questions “Have you smoked at least 100 cigarettes during 945 
your entire life?” and “Do you smoke cigarettes now?” Participants were coded as ‘never’ smokers if they had not 946 
smoked at least 100 cigarettes and did not currently smoke cigarettes; ‘former’ smokers had smoked at least 100 947 
cigarettes but did not currently smoke, and ‘current’ smokers responded affirmatively to both questions. Three 948 
dummy variables were created for race-ethnicity (Non-Hispanic white, Non-Hispanic black, and Mexican-949 
American). Three dummy variables were also created for years of education (less than high school education, high 950 
school graduate, and college graduate). Self-reported history (y/n) of doctor diagnosed diabetes, cancer, and 951 
cardiovascular disease were included as binary variables in all models. Dietary behaviors including intentional 952 
weight loss in the last year (y/n), dietary changes in the last year (y/n), and whether intake on the dietary recall was 953 
less than, more than, or comparable to their usual day were included as covariates. Total kilocalories, percent 954 
kilocalories from fat, carbohydrate, and non-BCAA protein were computed from the 24-hour recall used to assess 955 
dietary intake. Total leisure-time physical activity was estimated by a physical activity questionnaire, which asked 956 
participants to report the frequency (over the past 30 days) of engaging in nine activities and up to four additional 957 
other activities not queried directly in the survey. Weekly frequencies of each activity were multiplied by a validated 958 
intensity rating in metabolic equivalents (MET) and summed for each individual. MET values used in NHANES III 959 
were defined by the Compendium of Physical Activities (Pate et al., 1995). Cox Proportional Hazard Models 960 
adjusted for covariates were used to evaluate the association between BCAA intake as a percent of total kilocalories 961 
and cancer mortality stratified by age group (50-66 and 66 and older). We also estimated the effect of replacing 962 
kilocalories from BCAA with carbohydrates and fat by examining the continuous multivariable-adjusted association 963 
between BCAA intake and cancer mortality while simultaneously including these macronutrients in the model. 964 
Effects of interchanging different macronutrients were estimated by computing the differences between linear 965 
coefficients and their corresponding covariance matrix to obtain HRs and 95% CIs (Bernstein et al., 2010). It was 966 
not possible to estimate the effect of replacing BCAA with non-BCAA protein due to multicollinearity (r=0.975), 967 
but in sensitivity analyses where non-BCAA protein intake was modeled as the primary exposure variable, 968 
associations with cancer mortality were attenuated. 969 
 970 
QUANTIFICATION AND STATISTICAL ANALYSIS 971 
Differentially expressed genes were quantified with the DESeq2 package in R. Genes with P-values<2.44x10-6 972 
(meeting genome-wide Bonferroni correction criteria) were considered significant. Kaplan-Meier survival estimate 973 
curves and associated statistics were generated with the Survival package in R. All analyses performed on the 974 
NHANES III dataset were conducted with SAS 9.4 software (SAS Institute). All remaining statistical analyses were 975 
performed in Microsoft Excel. Unless otherwise noted, a homoscedastic two-tailed Student’s t-test was performed 976 
and considered significant if P<0.05. Standard error of the mean (s.e.m.) are shown for all quantitative data, except 977 
when smaller than data point symbols (cell proliferation growth curves) or for clarity (heat maps and dot plots). 978 
 979 
DATA AND SOFTWARE AVAILABILITY 980 
Gene expression profiles have been deposited at the Gene Expression Omnibus (GEO) under the accession number 981 
GSE75677. 982 
 983 
Supplemental Figure Legends 984 
Figure S1. BCAA Catabolism Is Suppressed in Hepatocellular Carcinomas and Predicts Patient Survival, 985 
Related to Figure 1 986 
(A) Patient characteristics of the cohort recruited at Singapore General Hospital (SGH), including total number, 987 
average age (range), and number (percent) of males, females, Hepatitis B+, Hepatitis C+, and indicated racial 988 
backgrounds. Additional information on tumor characteristics of the cohort can be found in Figure 1H. 989 
(B) Summary of differential expression analysis from paired HCCs and nontumor liver tissues of the SGH cohort.  990 
(C-E) Immunoblots for BCAT1 and BCAT2 in (C) HCCs and nontumor liver tissues from patients of the SGH 991 
cohort, (D) liver-derived cancer cell lines, and (E) normal, tumor, and regenerating liver tissues of animal models. 992 
(F) Representative immunohistochemical micrographs from nontumor liver tissue and HCC biopsies, as profiled by 993 
The Human Protein Atlas.  994 
(G) Summary of metabolites that were not significantly different in paired HCCs and nontumor liver tissues from 995 
patients of the SGH cohort. Data are shown as mean ± s.e.m. 996 
(H) Summary of BCAA catabolic enzyme transcript levels in HCCs from the SGH and TCGA cohorts, sorted by 997 
race/ethnicity, tumor etiology, and extratumoral liver inflammation, as well as the association of these characteristics 998 
with tumor aggressiveness.  999 
(I) Quantification of cox proportional hazard ratios (95% confidence intervals), significance (log-rank P-value), 1000 
robustness, and difference in days of estimated survival for patients of the TCGA-LIHC cohort with low expression 1001 
of indicated BCAA catabolic enzymes. 1002 
 1003 
Figure S2. Loss of BCAA Catabolism Occurs in Liver Cancers but Not Regenerating Liver Tissues, Related 1004 
to Figure 2 1005 
(A) KEGG pathway analysis of all 1202 genes significantly different in DEN and orthotopic (Morris Hepatoma) 1006 
tumor models (without exclusion of genes significantly different in regenerating tissues).  1007 
(B) KEGG pathway analysis of the 226 genes shared by regenerating tissues, and DEN and orthotopic tumors.  1008 
(C) RT-PCR analysis of BCAA catabolic enzymes from rat tumor and regenerating tissues, normalized to normal 1009 
liver tissues.  1010 
(D) RT-PCR analysis of BCAA catabolic enzymes from mouse tumor tissues, normalized to nontumor liver tissue.  1011 
(E) Expression summary of all 976 genes identified in the transcriptomic analysis. DEN tumor tissues are compared 1012 
to DEN nontumor tissues (mouse), and Morris Hepatoma and regenerating liver tissues are compared to normal liver 1013 
tissues (rat).  1014 
(F) Summary of expression changes in the top five KEGG pathways.  1015 
(G) Non-targeted metabolomics analysis of rat DEN-induced tumors, Morris hepatoma tumors, and regenerating 1016 
tissues, normalized to normal liver tissues.  1017 
(H) Quantification of immunoblots presented in Figure 2F, normalized to respective normal liver tissue controls.  1018 
(I) Representative BCKDK immunohistochemical micrographs from nontumor liver tissue and HCC biopsies, as 1019 
profiled by The Human Protein Atlas.  1020 
(J) Quantification of ex vivo BCKDH complex activity in normal liver tissues and DEN-induced tumors in rats.  1021 
(K) Representative coronal FLASH MRI images of DEN-induced liver tumors and normal liver from rats used in 1022 
the MRS analyses. 1023 
*P<0.05, §P<0.01, compared to respective controls. Data are shown as mean ± s.e.m. 1024 
 1025 
Figure S3. Reduced BCAA Catabolic Enzyme Expression Is Associated with Copy Number Variations and 1026 
Transcription Factor Alterations, Related to Figure 3 1027 
(A) Ingenuity Pathway Analysis identifying predicted upstream regulators of all significant, differentially expressed 1028 
genes of TCGA human liver cancers, animal models (different in tumors but not regenerating tissues), and 1029 
specifically the BCAA catabolic enzymes.  1030 
(B) Summary of transcription factor expression in HCCs from the TCGA-LIHC cohort, sorted by stage, grade, 1031 
vascular invasion, and local invasion.  1032 
(C) Kaplan-Meier survival estimate curves for TCGA-LIHC patients ranked by expression of indicated transcription 1033 
factors. P-values for log-rank test shown.  1034 
(D) Transfac analysis identifying enriched transcription factor sequence motifs in the promoters of all significant, 1035 
differentially expressed genes of human liver cancers, animal models (different in tumors but not regenerating 1036 
tissues), and specifically the BCAA catabolic enzymes.  1037 
(E) Summary of ENCODE ChIP-seq data identifying enriched transcription factors bound to the promoters of 1038 
BCAA catabolic enzymes.  1039 
(F) RT-PCR analysis of BCAA catabolic enzymes from HepG2 cells expressing shRNAs to PPARα or nontargeting 1040 
control. 1041 
(G) Summary of all non-silent mutations of the TCGA-LIHC in proteins related to the nutrient-sensing arm of 1042 
mTORC1. 1043 
*P<0.05, compared to respective controls. Data are shown as mean ± s.e.m. 1044 
 1045 
Figure S4. BCAA Catabolism Regulates mTORC1 Activity and in vitro Cell Proliferation, Related to Figure 4 1046 
(A) Immunoblots of the mTORC1 downstream effector S6K in animal liver tumor and regenerating models. 1047 
(B) “mTORC1 signaling” enrichment plots from gene set enrichment analysis (GSEA) of the 1405 human HCC and 1048 
976 animal tumor model (nor regenerating) data sets. 1049 
(C) Real-time proliferation curves, immunoblots detailing knockdown efficiency (BCKDHA) and mTORC1 1050 
pathway activity (p-S6KThr389 to total S6K, and p-S6Ser235/236 to total S6 ratios), and intracellular BCAA content of 1051 
AML12 cells expressing a tet-inducible non-targeting control or BCKDHA shRNAs, in the absence or presence of 1052 
doxycycline and/or the mTOR inhibitors rapamycin (0.05nM) or Torin 1 (0.5nM).  1053 
(D) Real-time proliferation curves of Hep3B cells grown in complete or BCAA-free media, with or without 3% 1054 
albumin, 30% FBS, and/or 100nM Torin 1. Similar results were obtained when using Leucine-free media and/or 1055 
Rapamycin.  1056 
(E) Summary of frame-shift mutations caused by CRISPR-Cas9-mediated insertions and/or deletions in the BCKDK 1057 
gene of Hep3B clones.  1058 
(F) Real-time proliferation curves of the liver cancer cell lines treated with the BCKDK inhibitor BT2, and 1059 
immunoblots after 2 hours of treatment.  1060 
(G-I), Characterization of liver cancer cell lines treated with the mTOR inhibitors Rapamycin or Torin 1. (G) 1061 
Representative real-time proliferation curves. (H) Calculation of proliferation rates (number of divisions per day). 1062 
(I) Immunoblots after 2 hours of treatment. 1063 
*P<0.05, compared to respective controls. Data are shown as mean ± s.e.m. 1064 
 1065 
Figure S5. Characterization of Mice on BCAA-Supplemented or -Restricted Diets, Related to Figures 5 and 6 1066 
(A) Summary of RT-PCR statistical analyses presented in Figure 5H, comparing tissues of LFD+BCAA, HFD, and 1067 
HFD+BCAA groups to corresponding tissues of the LFD group. 1068 
(B) Quantification of nontumor liver tissue amino acid content of DEN-injected mice fed indicated diets, 5 months 1069 
post injection, normalized to the LFD group. *P<0.05 vs. LFD. §P<0.05 vs. HFD. 1070 
(C) Quantification of tumor and nontumor liver tissue amino acid content of DEN-injected mice fed indicated diets, 1071 
8 months post injection, normalized to respective LFD groups. *P<0.05 vs. LFD. 1072 
(D) Quantification of tumor and nontumor liver tissue acylcarnitine content from DEN-injected mice fed indicated 1073 
diets, 8 months post injection, normalized to nontumor tissue of the LFD group. *P<0.05 vs. nontumor LFD, 1074 
§P<0.05 vs. tumor LFD. 1075 
(E) RT-PCR analysis of cytokines and F4/80 (encoded by ADGRE1) in normal liver tissue (from uninjected mice), 1076 
and nontumor and tumor liver tissues (from DEN-injected mice). Results normalized to normal liver tissue of LFD-1077 
fed mice. 1078 
(F) Representative histological analyses of livers from DEN-injected mice fed indicated diets, 5 months post 1079 
injection. 1080 
(G) Quantification of immunohistochemical staining related to Figures 5K and S5G as percent area (picosirius red) 1081 
or percent positive cells (remaining), n ≥ at least two random fields per sample, and at least 3 samples per group. 1082 
(H) Characterization of DEN-injected mice fed standard chow diets, or chow diets with 0.02% BT2 added, including 1083 
quantification of the number of tumors (≥3mm) and size of the largest tumor per mouse. 1084 
(I) Summary of RT-PCR statistical analyses presented in Figure 6I, comparing tissues of LFD-lowBCAA and 1085 
LFD+BCAA groups to corresponding tissues of the LFD group. 1086 
(J) Quantification of immunohistochemical staining related to Figure 6G as percent area (picosirius red) or percent 1087 
positive cells (remaining), n ≥ at least two random fields per sample, and at least 3 samples per group. 1088 
Data are shown as mean ± s.e.m. 1089 
 1090 
Figure S6. The Impact of Tissue BCAA Catabolism on Cancer Development and Progression, Related to 1091 
Figure 7 1092 
(A) Oncomine analysis of mRNA expression datasets profiling various cancers compared to nontumor controls. 1093 
Colors reflect the degree of over- or under-expression, and numbers reflect the quantity of studies included in the 1094 
summation.  1095 
(B) Quantification of cox proportional hazard ratios (95% confidence intervals), significance (log-rank P-value), 1096 
robustness, and difference in days of estimated survival for patients of the TCGA COADREAD, STAD, ACC, 1097 
KIRC, and KICP cohorts with low expression of indicated BCAA catabolic enzymes. 1098 
(C) Immunoblots for mTOR pathway activity in HepG2 cells cultured in complete media, or cultured in BCAA-free 1099 
media for 4 hours, then stimulated with indicated concentrations of leucine or α-ketoisocaproate (KIC) for 10 1100 
minutes.  1101 
(D-F) BCAT1 inhibition in HepG2 cells. (D) Real-time proliferation curves of HepG2 cells grown in complete 1102 
media treated with the BCAT1 inhibitor gabapentin. (E) Immunoblots of HepG2 cells 4 hours after gabapentin 1103 
treatment. (F) Real-time proliferation curves of HepG2 cells grown in BCAA-free media treated with gabapentin. 1104 
 1105 
Figure S7. The Impact of BCAA Tissue Catabolism and Dietary Intake on Overall Cancer Mortality, Related 1106 
to Figure 7 1107 
(A) Kaplan-Meier survival estimate curves of all cancers profiled by TCGA with at least 15 verified deaths. Within 1108 
each cancer, individuals were ranked by a combined expression index of ACADS, ACADSB, and BCKDHA, and top 1109 
and bottom quartiles were compared.  1110 
(B) Kaplan-Meier survival estimate curve of the normalized pan-cancer dataset by TCGA. Individuals were ranked 1111 
by a combined expression index of ACADS, ACADSB, and BCKDHA, and top and bottom quartiles were compared. 1112 
Cox proportional hazard ratio (HR) for low expression group, and p-value for log-rank test shown.  1113 
(C) Population characteristics of NHANES III participants, aged 50-66 years old. Data presented as mean (with 1114 
standard error).  1115 
(D) Change in cancer mortality risk associated with increasing BCAA or non BCAA protein content by 1% kcal in 1116 
the 50-66 year old cohort.  1117 
(E-G) Analysis of cancer mortality risk of individuals >66 years-old. (E) Hazard ratios (with 95% confidence 1118 
interval) based on BCAA intake, 1adjusted for age, sex, race, total kcal, usual dietary intake, diet change, physical 1119 
activity, intentional weight loss, waist circumference, smoking, education, and prior diagnosis of cancer, diabetes 1120 
and cardiovascular disease, 2additionally adjusted for % kcal from other macronutrients. (F) Change in cancer 1121 
mortality risk associated with increasing BCAA or non-BCAA protein content by 1% kcal. (G) Substitution analysis 1122 
comparing change in risk when replacing BCAAs with carbohydrate or fat, with the same adjustments as HR2 1123 
except total kcal and % kcal from non-BCAA protein. Data are presented as hazard ratio (solid line) with 95% 1124 
confidence interval (shaded area). 1125 
(H) Summary of LAT transporter expression in the animal tumor and regenerating models (mean ± s.e.m.), and 1126 
human HCC (mean ± s.d.; TCGA-LIHC cohort).  1127 
(I) Kaplan-Meier survival estimate curves for patients ranked by tumor LAT transporter expression. P-values for 1128 
log-rank test shown. 1129 
*P<0.05, compared to respective controls. 1130 
 1131 
Table S1. Rodent Diet Composition, Related to STAR Methods 1132 
Summary of % of kcal, and source of the fat, carbohydrate, and protein used in the rodent studies. Diets with 1133 
supplemented BCAAs (+BCAA) included an additional 150% of purified leucine, isoleucine, and valine over 1134 
baseline levels. Diets with restricted BCAAs (-lowBCAA) lowered leucine, isoleucine, and valine to 50% of 1135 
baseline levels. *LFD-lowAA and LFD+AA diets were used to control for any possible effects of total protein 1136 
content in LFD-lowBCAA and LFD+BCAA diets, respectively. Baseline BCAA levels were maintained, while all 1137 
other amino acids were adjusted proportionally. 1138 
 1139 
Table S2. Real-time PCR Primer Sequences, Related to STAR Methods 1140 
Primer sequences used for human, mouse, and rat samples. 1141 
KEGG Term p Value
Valine, leucine and isoleucine degradation
Cell cycle
DNA replication
Fatty acid degradation
Butanoate metabolism
Rank
2
1
3
4
5 6.7E-05
9.1E-08
2.0E-08
1.7E-09
8.6E-10
C DB
TCGA-LIHC
SGH
1405
Nontumor
Tumor
Nontumor
Tumor
SGH
TCGA-LIHC
48
48
50
371
n
B
C
AT1
B
C
AT2
D
LD
A
U
H
A
C
A
D
8
A
LD
H
3A
2
A
C
AT2
H
A
D
H
B
M
C
C
C
2
P
C
C
B
H
S
D
17B
10
H
A
D
H
A
H
IB
A
D
H
A
LD
H
9A
1
M
C
C
C
1
M
C
E
E
B
C
K
D
H
A
D
B
T
H
IB
C
H
M
U
T
P
C
C
A
H
A
D
H
B
C
K
D
H
B
A
LD
H
1B
1
A
C
A
D
M
IV
D
H
M
G
C
L
E
C
H
S
1
H
M
G
C
S
2
A
C
AT
E
H
H
A
D
H
A
B
AT
A
C
A
A
1
A
C
A
D
S
B
A
C
A
A
2
A
LD
H
2
A
C
A
D
S
A
LD
H
6A
1-2 2
Relative gene 
expression
ACADSB
ACADS
BCKDHA
NT T NT T NT T NT T NT TNontumor/Tumor
P34 P22 P37 P45 P40
GAPDH
Patient
E 25
20
15
10
5
0
BCKDH activity
nm
ol
/g
/m
in
No
ntu
mo
r
Tu
mo
r
*
A 4
2
0
-2
-4
SG
H 
Δe
xp
re
ss
io
n
p < 1x10-8
Remaining
-6 -3 0 3 6 9
TCGA-LIHC Δexpression G
H
R
el
at
iv
e 
co
nt
en
t
Nontumor
Tumor
3
2
1
0
Le
u Ile Va
l
Ph
e
Me
t
Se
r
Gl
x
Ar
g
La
cta
te
Fu
me
ra
te
Ma
lat
e C2 C3 C6
C6
:1-
DC
C1
0:1 C1
0
C7
-D
C
C8
:1-
DC
C1
4:1
-D
C
C1
4-
DC
C1
6:1
-D
C
C1
6-
DC C2
0
C1
8-
DC
Amino acids Organic acids Acylcarnitines
* * *
* * * *
*
*
* *
*
* * * * * * *
*
* *
*
* *
HR = 1.8 (1.1-2.9)
p=3.9E-6
Survival (days)
0 1000 2000 3000
100
80
60
40
20
0
n=89
n=241
%
 p
at
ie
nt
 s
ur
vi
va
l
TCGA-LIHC
HR = 2.6 (0.6-11.6)
p=0.19
Survival (days)
0 1000 2000 3000
100
80
60
40
20
0
n=35
n=13
%
pa
tie
nt
 s
ur
vi
va
l
SGH
4000
Survival (days)
0 1000 2000 3000
100
80
60
40
20
0
n=89
n=32
p=4.5E-4
HR = 4.9 (1.5-16.3)
TCGA-LIHC (high grade)
%
 p
at
ie
nt
 s
ur
vi
va
l
J
High
Low
Trigene Expression
(BCKDHA, ACADS, ACADSB)
I
164
82
67
16
51
171
116
12
174
89
76
196
104
n
None
Stage I
Stage II
StageIIIA
Stage IIIB/C
Grade 1
Grade 2
Grade 3
Grade 4
Stage
Grade
Local 
invasion
Vascular 
invasion
T1
T2
T3
Invasive
TCGA-LIHC
25
13
10
3
21
19
5
25
13
10
42
6
nSGH
M1
Stage I
Stage II
StageIII
Grade 1
Grade 2
Grade 3
Grade 4
T1
Stage
Grade
Local 
invasion
Metastasis
T2
T3
M0
ACADSBCKDHA ACADSB
Tu
m
or
N
or
m
al
F
-2
2
R
el
at
iv
e 
ge
ne
 
ex
pr
es
si
on
Val Leu Ile Phe Asn Met
6
4
2
0R
el
at
iv
e 
C
on
te
nt
Tumors, not regenerating
*
*
* * * * * * *
*
*
*
Gln GlyArg
None
nd
LysAla Tyr
Morris hepatoma only
* *
*
Asp Cys SerGlu ThrHis
12
9
6
3
0R
el
at
iv
e 
C
on
te
nt
DEN only
Tumors + regenerating
* *
**
*
*
*
*
*
*
* * *
*
DEN nontumor
DEN tumor
Normal liver
Orthotopic tumor
Regenerating
Amino AcidsDB
C
A
DEN tumor
Orthotopic
tumor
Regenerating
226
976
G
DEN nontumor
DEN tumor
Normal liver
Orthotopic tumor
Regenerating
Normal liver
BCKDH activity
*
*
**
nm
ol
es
/g
/m
in
100
75
50
25
0
2.5
2.0
1.5
1.0
0.5
0
Phospho:
Total BCKDHA
*
*
**
R
at
io
E
Normal liver DEN nontumor DEN tumor Normal liver
Orthotopic 
tumor Regenerating
GAPDH
p-BCKDHASer293
BCKDHA
ACADS
ACADSB
F
Normal liver
DEN 
nontumor
DEN 
tumor
Cox IV
BCKDK
Orthotopic 
tumor RegeneratingNormal liver
Cox IV
BCKDK
H I
Normal liver
DEN tumor
KIC
Leucine
0.004
0.002
0
*
Bicarbonate
n=
4
n=
4
α-Ketoisocaproate Isovaleryl-CoA
CO2* H CO3* -
Bicarbonate
BCAT
BCKDHO
C
OH
O
*
O
S
CoA
Leucine
NH2
C
OH
O
*
J
†
Acylcarnitines
DEN tumor
Orthotopic tumor
Regenerating0.1
10
1
12.5
10.8 11.3
R
at
io
 o
f c
on
tro
l
C
2
C
4/
C
i4
C
5:
1
C
5
C
4-
O
H
C
4/
C
i4
-D
C
C
8:
1
C
8
C
5-
D
C
C
10
:1
C
7-
D
C
C
12
C
10
:1
-D
C
C
12
:3
-D
C
C
12
:2
-D
C
C
16
:3
C
16
C
14
-D
C
C
18
:3
C
18
:2
C
18
:1
C
18
C
16
:2
-D
C
C
16
:1
-D
C
C
16
-D
C
C
20
:4
C
20
:3
C
20
:2
C
20
:1
C
20
C
18
:2
-D
C
C
18
:1
-D
C
C
22
:6
C
22
:5
C
22
:4
C
22
:3
C
22
:2
C
22
:1
C
22
†† †
‡
† †
‡
†
3
3
3
4
4
DEN nontumor
DEN tumor
Normal liver
Orthotopic tumor
Regenerating
n
H
A
D
H
B
H
A
D
H
A
D
B
T
D
LD
H
IB
C
H
A
C
AT1
A
C
A
D
S
M
C
C
C
1
H
S
D
17B
10
H
M
G
C
L
A
C
A
D
M
A
LD
H
9A
1
E
C
H
S
1
E
H
H
A
D
H
B
C
K
D
H
B
M
C
C
C
2
H
A
D
H
A
LD
H
2
A
C
A
A
1
A
U
H
B
C
K
D
H
A
M
U
T
A
C
A
D
8
A
C
A
A
2
P
C
C
A
A
O
X
1
A
LD
H
3A
2
A
C
A
D
S
B
H
IB
A
D
H
IV
D
H
M
G
C
S
2
A
LD
H
6A
1
A
B
AT-2 2
Relative gene 
expression
KEGG Term p Value
Valine, leucine and isoleucine degradation
Fatty acid metabolism
Primary bile acid synthesis
Glycine, serine and threonine metabolism
Tryptophan metabolism
Rank
2
1
3
4
5 6.6E-06
3.7E-06
1.6E-06
6.8E-07
2.3E-11
B
C
K
D
H
B
D
B
T
A
C
A
D
8
A
LD
H
9A
1
H
M
G
C
S
2
D
LD
IL4I1
H
M
G
C
L
B
C
K
D
H
A
E
C
H
S
1
A
C
A
D
M
H
IB
C
H
H
A
D
H
B
A
LD
H
3A
2
M
C
C
C
1
P
C
C
A
H
A
D
H
M
U
T
A
C
AT
A
C
AT2
H
IB
A
D
H
IV
D
H
A
D
H
A
A
C
A
A
2
A
C
A
D
S
P
C
C
B
A
LD
H
2
M
C
C
C
2
A
C
A
A
1
A
U
H
A
LD
H
1B
1
M
C
E
E
A
O
X
1
E
H
H
A
D
H
A
LD
H
6A
1
A
C
A
D
S
B
A
B
AT
Tubulin
He
pG
2
Hu
h7
He
p3
B
Sn
u4
49
Sn
u3
98
Sn
u3
87
Sn
u1
82
ACADSB
ACADS
BCKDHA
C D
R
ea
lti
ve
 m
R
N
A
1.5
1.0
0.5
0
Vehicle
2µM
10µM GW6471
AC
AA
1
AC
AA
2
AC
AD
SB
AC
AD
S
AC
AD
M
AL
DH
6A
1
BC
KD
HA DL
D
HA
DH
HM
GC
S2
*
*
*
*
*
* *
*
*
* ** *
*
*
*
**
*
E
B
A
B
AT
A
C
A
A
1
A
C
A
A
2
A
C
A
D
8
A
C
A
D
M
A
C
A
D
S
A
C
A
D
S
B
A
C
AT
1
A
C
AT
2
A
LD
H
1B
1
A
LD
H
2
A
LD
H
3A
2
A
LD
H
6A
1
A
LD
H
9A
1
A
O
X
1
A
U
H
B
C
K
D
H
A
B
C
K
D
H
B
D
B
T
D
LD
E
C
H
S
1
E
H
H
A
D
H
H
A
D
H
H
A
D
H
A
H
A
D
H
B
H
IB
A
D
H
H
IB
C
H
H
M
G
C
L
H
M
G
C
S
2
H
S
D
17
B
10 IV
D
M
C
C
C
1
M
C
C
C
2
M
C
E
E
M
U
T
P
C
C
A
P
C
C
BR
el
at
iv
e 
ge
ne
 e
xp
re
ss
io
n 2.5
1.5
0.5
-0.5
-1.5
-2.5
Normal tissue
Tumor-CNV normal
Tumor-CNV loss
A
HepG2
Huh7
Hep3B
SNU449
SNU398
SNU387
SNU182
HSD17B10
ACAT2
BCKDHB
MUT
ACAA2
ACAD8
ACAT1
AUH
ALDH1B1
HADH
ABAT
HMGCL
ACADM
DBT
HMGCS2
ACAA1
EHHADH
MCCC1
PCCB
BCAT1
ACADS
ALDH2
ALDH3A2
ALDH6A1
ACADSB
ECHS1
IVD
BCAT2
IL4I1
BCKDHA
PCCA
HIBCH
MCEE
HADHA
HADHB
MCCC2
OXCT1
DLD
HIBADH
ALDH9A1
26.8
37.8
30
2.7
25.4
24.9
24.3
31.1
27
46.5
28.1
37.3
24.6
24.3
19.2
14.3
11.4
11.4
11.1
18.6
14.6
11.9
38.1
34.6
28.6
28.1
19.5
10.8
10.8
10.5
25.7
10
10
7.8
7.8
13
4.9
7.6
4.3
0.8
Percent
Patients CNV loss
C0 1 2 3 4 5
Hep3B proliferation
C
el
l I
nd
ex
8
4
0
Days
Co
mp
let
e
-B
CA
As
 1h
r
p-S6K
S6K
S6
p-S6
Tubulin
Ser235/236
Thr389
Complete RPMI
-50% BCAAs
-75% BCAAs
-90% BCAAs
BCAA-Free
B
0 1 2 3 4 5
8
4
0
C
el
l I
nd
ex
BCKDHA tet-
on shRNA1
Days
-Dox
+Dox
+Dox +Rapamycin
+Dox +Torin 1
AML12 proliferation
1.8
1.2
0.6
0
BCKDHA shRNA1
-Dox
+Dox
+Dox+Rapamycin
+Dox+Torin 1
BCAAs
R
el
at
iv
e 
C
on
te
nt
* * *
Torin 1
BCKDHA
Dox
Rapamycin
++
+
+
+
Tubulin
p-S6
p-S6K
S6K
S6
Ser235/236
Thr389
NT T NT T NT T NT T NT TNontumor/Tumor
P34 P22 P37 P45 P40
GAPDH
Patient
p-S6
p-S6K
S6K
S6
Ser235/236
Thr389
A
D
0 1 2 3 4 5
Days
C
el
l I
nd
ex
25
20
15
10
5
0
Hep3B proliferation
pLOC Control
Flag-ACADS
Flag-ACADSB
Flag-BCKDHA
S6K
S6
p-S6Ser235/236
p-S6KThr389
pL
OC
Fla
g-
BC
KD
HA
Fla
g-
AC
AD
S
Fla
g-
AC
AD
SB
Tubulin
Flag
E
0 1 2 3 4 5
Days
C
el
l I
nd
ex
25
20
15
10
5
0
Hep3B proliferation
BCKDK 
null
pLenti Control
Clone #1
Clone #2
Clone #3
pL
en
ti C
on
tro
l
Cl
on
e #
1
Cl
on
e #
2
Cl
on
e #
3
BCKDK null
BCKDK
Cox IV
p-S6K
S6K
S6
Tubulin
p-S6Ser235/236
Thr389
F
C
el
l i
nd
ex
-12 0 12 24 36 48 60 72
8
6
4
2
0
Hours
Hep3B proliferation
BT2 
Vehicle
50µM 
150µM 
250µM
Ve
hic
le
50
µM
15
0µ
M
25
0µ
M
BT2 
p-S6K
S6K
S6
Tubulin
p-S6Ser235/236
Thr389
Mo
rri
s
he
pa
tom
a
He
p3
B
Sn
u4
49
Hu
h7
Sn
u3
87
Sn
u3
98
Sn
u1
82
2
1
0
# 
of
 d
iv
is
io
ns
/d
ay *
*
*
*
*
*
*
*
*
*
**
**
*
*
**
*
Proliferation rates
BT2 
Vehicle
50µM 
150µM 
250µM
G
H Control
M
er
ge
m
TO
R
-Amino Acids BT2
LA
M
P2
90
60
30
0
P
er
ce
nt
 o
ve
rla
p
Co
ntr
ol
-A
mi
no
 ac
ids BT
2
*
*
I
HA
pLOC
control
HA-RagBS75L/
HA-RagCQ99L
BT2 
Ve
hic
le
50
µM
15
0µ
M
25
0µ
M
Ve
hic
le
50
µM
15
0µ
M
25
0µ
M
BT2 
p-S6K
S6K
S6
Tubulin
p-S6Ser235/236
Thr389
Flag
BT2 
Ve
hic
le
50
µM
15
0µ
M
25
0µ
M
Ve
hic
le
50
µM
15
0µ
M
25
0µ
M
BT2 
Flag-
Raptor
Flag-Raptor-
Rheb15
p-S6K
S6K
S6
Tubulin
p-S6Ser235/236
Thr389
J
BT2 
Ve
hic
le
50
µM
15
0µ
M
25
0µ
M
Ve
hic
le
50
µM
15
0µ
M
25
0µ
M
BT2 
GFP
shRNA
Sestrin 1/2/3
shRNA
p-S6K
S6K
S6
Tubulin
p-S6Ser235/236
Thr389
Sestrin2
Tumor multiplicity
Tu
m
or
s/
m
ou
se
12
9
6
3
0
*
*
* 16
12
8
4
0
Largest tumor
La
rg
es
t t
um
or
pe
r m
ou
se
 (m
m
) *
§* §
Tumor incidence
100
75
50
25
0
%
 m
ic
e 
w
ith
 tu
m
or
s
GD
         LFD             LFD+BCAA             HFD              HFD+BCAA
        LFD              LFD+BCAA              HFD             HFD+BCAA
A
Uninjected DEN
15
10
5
0P
er
ce
nt
 o
f b
od
y 
w
ei
gh
t
LFD
LFD+BCAA
HFD
HFD+BCAA
Normalized liver mass
n=
5
n=
5
n=
5
n=
5
n=
5
n=
5
n=
5
n=
5
Tumor sizes
P
er
ce
nt
Tumor incidence
100
75
50
25
0
M
ill
im
et
er
s
15
10
5
0
B C
P
er
ce
nt
 o
f b
od
y 
w
ei
gh
t 15
10
5
0
LFD
LFD+BCAA
HFD
HFD+BCAA
Uninjected DEN
Normalized liver mass
n=
5
n=
5
n=
9
n=
10
n=
8
n=
10
n=
11
n=
12
E
Fo
ld
 c
ha
ng
e
2.5
2.0
1.5
1.0
0.5
0
ABAT ACAA1 ACAA2 ACADS ACADSB ALDH6A1 BCKDHA ECHS1 HIBCH HMGCS2 MCCC1
H
F
L
LFD
LFD
+BCAA
HFD
+BCAA
HFD
Histology
(Hematoxylin & eosin)
Fibrosis
(Picosirius red)
Proliferation
(Ki67)
Cell death 
(Cleaved caspase 3)
Tumor
Nontumor
Nontumor
Tumor
Nontumor
Tumor
Nontumor
Tumor
DNA damage
(p-H2A.XSer139)
200µm
KLFD LFD+BCAA HFD HFD+BCAA
Uninjected
DEN nontumor
DEN tumor
Uninjected
DEN nontumor
DEN tumor
Uninjected
DEN nontumor
DEN tumor
Uninjected
DEN nontumor
DEN tumor
Nontumor
BCAAs2.0
1.5
1.0
0.5
R
el
at
iv
e 
co
nt
en
t * *
*
JI
Tumor BCAAs
2.0
1.5
1.0
0.5
§§
R
el
at
iv
e 
co
nt
en
t
Number of tumors
125
100
75
50
0 5 10 15 20 25
N
on
tu
m
or
 B
C
A
A
s 
(µ
M
)
R2 = 0.65
HFD+BCAAHFDLFD+BCAALFD
5
4
3
2
1
0
* *
*Phospho:Total S6K
R
at
io
LFD
GAPDH
S6K
p-S6KThr389
LFD
+BCAA HFD
HFD
+BCAA
HFD+BCAAHFDLFD+BCAALFD
1cm
1cm
*
Lean mass
Uninjected DEN
30
20
10
0
G
ra
m
s
D
12
9
6
3
0
Average tumor size
m
ill
im
et
er
s
*
*
E F Nontumor BCAAs
p=0.08
*
R
el
at
iv
e 
co
nt
en
t
2.0
1.5
1.0
0.5
0
A
LFD+BCAA LFD+BCAA+BT2 HFD+BCAA
HFD+BCAA
+BT2
LFD+BCAA
LFD+BCAA+BT2
HFD+BCAA
HFD+BCAA+BT2
B
La
rg
es
t t
um
or
pe
r m
ou
se
 (m
m
)
14
7
0
Largest tumor
‡
†
Tu
m
or
s/
m
ou
se
5
4
3
2
1
0
Tumor multiplicity
† ‡
n=
17
n=
13
n=
12
n=
13
C LFD-lowBCAA
LFD
LFD+BCAA
S
ur
vi
va
l (
%
)
100
90
80
70
60
50
Months post injection
20 64 108 12
(n=14)
(n=15)
(n=25)
Log-rank p-value
LFD-lowBCAA vs LFD: <0.10
LFD-lowBCAA vs LFD+BCAA: <0.05
P
er
ce
nt
 o
f b
od
y 
w
ei
gh
t
Uninjected
Normalized liver mass
DEN
16
12
8
4
0 n
=1
0
n=
19
n=
9
n=
9
n=
12
n=
7
Uninjected
DEN nontumor
DEN tumor
Uninjected
DEN nontumor
DEN tumor
Uninjected
DEN nontumor
DEN tumor
LFD-lowBCAA LFD LFD+BCAA
LFD-lowBCAA
LFD
LFD+BCAA
H
I
G
Nontumor
Tumor
Nontumor
Tumor
Nontumor
Tumor
LFD-
lowBCAA
LFD
LFD+BCAA
Proliferation
(Ki67)
Fibrosis
(Picosirius red)
DNA damage
(p-H2A.XSer139)
Histology
(Hematoxylin & eosin)
Cell death 
(Cleaved caspase 3)
 LFD-lowBCAA           LFD              LFD+BCAA    
2
1
0
Fo
ld
 c
ha
ng
e
ABAT ACAA1 ACAA2 ACADS ACADSB ALDH6A1 BCKDHA ECHS1 HIBCH HMGCS2 MCCC1
*
*
1cm
1cm
BCAAs of total protein (%)
Total protein content (%)
9 19 14 34
15 15 21 21
12
9
6
3
0
m
ill
im
et
er
s
*
*
ns
LFD-lowBCAA
LFD-lowAA
LFD+AA
LFD+BCAA
Average tumor sizeJ
Enzymes
Metabolites
EHHADH
MUT MCEE
Leucine
Valine
ACADSB ACADS
HIBCH
BCAT1 BCAT2
ACAD8
Isoleucine
ACADSB ACADS
ECHS1
BCAT1 BCAT2
ACADM
EHHADH
HIBADH
EHHADH
ALDH3A2
ABAT
ALDH1B1ALDH9A1
AOX1ALDH7A1
ALDH2 ALDH6A1
PCCA PCCB
ACAA1 ACAA2
HADHHSD17B10
HADH
HADH ECHS1
EHHADH
BCAT1 BCAT2
ACADMIVD
MCCC1 MCCC2
AUH
HMGCL
HMGCS
BCKDHB
DLD
BCKDHA
DBT
HADH
HADHB
C5:1
BCKDHB
DLD
BCKDHA
DBT BCKDHB
DLD
BCKDHA
DBT
C3
A n
Normal
Tumor
Normal
Tumor
Normal
Tumor
Hepatocellular & cholangio carcinoma
Kidney renal clear cell carcinoma
Head & neck squamous cell carcinoma
-2 2Relative gene expression
Normal
Tumor
Normal
Tumor
Normal
Tumor
Normal
Tumor
Normal
Tumor
Normal
Tumor
Normal
Tumor
Normal
Tumor
Normal
Tumor
Normal
Tumor
Normal
Tumor
Normal
Tumor
Colorectal adenocarcinoma
Kidney renal papillary cell carcinoma
Stomach adenocarcinoma
Breast invasive carcinoma
Kidney chromophobe
Esophageal carcinoma
Thyroid carcinoma
Lung squamous cell carcinoma
Bladder urothelial carcinoma
Lung adenocarcinoma 
Prostate adenocarcinoma
Uterine corpus endometrial carcinoma
59
407
72
533
43
519
50
380
32
290
37
384
113
1095
25
66
13
184
59
505
51
502
19
407
58
511
52
497
24
174B
C
AT2
B
C
AT1
IL4I1
O
X
C
T1
D
LD
H
A
D
H
A
A
U
H
A
C
A
D
8
A
LD
H
3A
2
H
A
D
H
B
M
C
C
C
1
H
M
G
C
S
2
A
O
X
1
H
S
D
17B
10
M
C
C
C
2
P
C
C
B
B
C
K
D
H
A
M
C
E
E
P
C
C
A
A
LD
H
9A
1
H
IB
A
D
H
A
C
AT2
H
IB
C
H
H
A
D
H
D
B
T
IV
D
E
C
H
S
1
A
C
A
D
M
A
LD
H
1B
1
H
M
G
C
L
M
U
T
A
C
AT1
B
C
K
D
H
B
A
C
A
A
1
A
C
A
A
2
A
C
A
D
S
A
LD
H
2
E
H
H
A
D
H
A
C
A
D
S
B
A
B
AT
A
LD
H
6A
1
B
C n
57
134
114
53
68
253
47
202
98
66
250
49
B
C
AT1
A
O
X
1
H
M
G
C
S
2
A
B
AT
A
C
AT2
A
C
A
A
1
H
A
D
H
A
A
C
A
A
2
M
U
T
E
H
H
A
D
H
A
LD
H
9A
1
P
C
C
A
A
C
A
D
8
M
C
E
E
H
M
G
C
L
B
C
K
D
H
A
H
A
D
H
B
A
U
H
H
IB
A
D
H
H
S
D
17B
10
H
IB
C
H
D
B
T
B
C
K
D
H
B
M
C
C
C
1
D
LD
A
LD
H
3A
2
IV
D
A
LD
H
1B
1
P
C
C
B
B
C
AT2
E
C
H
S
1
A
LD
H
2
A
LD
H
6A
1
H
A
D
H
A
C
A
D
S
M
C
C
C
2
A
C
A
D
M
A
C
AT
A
C
A
D
S
B
Colorectal adenocarcinoma
Stage I
Stage II
Stage III
Stage IV
T1/2
T3
T4
Local 
invasion 
Lymph node 
invasion
Metastasis
N0
N1
N2
M0
M1
51
116
174
31
20
74
172
118
100
150
341
19
A
O
X
1
B
C
AT1
H
M
G
C
S
2
H
S
D
17B
10
A
LD
H
1B
1
A
C
A
A
2
H
IB
A
D
H
P
C
C
A
A
C
AT
B
C
AT2
IV
D
D
B
T
P
C
C
B
A
C
A
D
8
M
C
C
C
1
A
C
A
A
1
M
C
C
C
2
A
B
AT
E
H
H
A
D
H
B
C
K
D
H
B
D
LD
A
U
H
A
LD
H
6A
1
M
U
T
A
C
AT2
A
LD
H
9A
1
B
C
K
D
H
A
M
C
E
E
A
C
A
D
S
B
A
C
A
D
M
H
A
D
H
B
H
IB
C
H
H
M
G
C
L
H
A
D
H
A
H
A
D
H
E
C
H
S
1
A
LD
H
2
A
LD
H
3A
2
A
C
A
D
S
Stomach adenocarcinoma n
Stage I
Stage II
Stage III
Stage IV
N0
N1
N2/3
M0
M1
Lymph node 
invasion
Metastasis
Local 
invasion
T1
T2
T3
Adrenocortical carcinoma
B
C
AT1
A
LD
H
1B
1
B
C
K
D
H
A
D
LD
A
C
A
D
M
M
C
C
C
2
A
C
AT2
H
S
D
17B
10
B
C
AT2
A
C
A
D
8
E
C
H
S
1
H
A
D
H
A
M
C
C
C
1
E
H
H
A
D
H
A
LD
H
3A
2
D
B
T
P
C
C
B
M
U
T
H
A
D
H
B
A
U
H
P
C
C
A
A
LD
H
9A
1
H
IB
A
D
H
IV
D
H
A
D
H
B
C
K
D
H
B
A
C
A
A
1
A
LD
H
6A
1
M
C
E
E
A
C
AT1
A
C
A
D
S
B
H
M
G
C
L
H
IB
C
H
A
LD
H
2
H
M
G
C
S
2
A
C
A
A
2
A
C
A
D
S
A
B
AT
A
O
X
1
Stage I
Stage II
Stage III
Stage IV
T1
T2
T3
Local 
invasion 
Metastasis
T4
M0
M1
n
9
36
16
15
9
41
8
18
61
15
A
O
X
1
B
C
AT1
A
C
AT2
H
S
D
17B
10
M
C
E
E
A
C
A
A
1
H
A
D
H
H
A
D
H
A
H
M
G
C
L
D
LD
E
C
H
S
1
P
C
C
B
H
IB
A
D
H
A
C
A
D
M
H
A
D
H
B
M
U
T
B
C
K
D
H
B
A
LD
H
1B
1
B
C
AT2
M
C
C
C
2
M
C
C
C
1
D
B
T
A
C
A
D
8
B
C
K
D
H
A
A
LD
H
9A
1
IV
D
A
LD
H
3A
2
A
U
H
A
C
A
D
S
H
IB
C
H
E
H
H
A
D
H
A
LD
H
6A
1
A
C
AT1
P
C
C
A
A
C
A
A
2
A
C
A
D
S
B
A
B
AT
A
LD
H
2
H
M
G
C
S
2
Stage I
Stage II
Stage III
Stage IV
T1
T2
T3
Local 
invasion 
T4
Kidney chromophobe n
21
25
14
6
21
25
18
2
B
C
AT1
A
C
AT2
H
S
D
17B
10
P
C
C
B
A
LD
H
1B
1
M
C
E
E
A
LD
H
2
B
C
AT2
E
C
H
S
1
A
C
A
A
1
M
C
C
C
1
M
C
C
C
2
D
LD
H
A
D
H
A
H
IB
A
D
H
H
M
G
C
L
H
A
D
H
B
D
B
T
A
C
A
D
8
B
C
K
D
H
A
IV
D
H
A
D
H
A
C
A
D
S
A
LD
H
9A
1
B
C
K
D
H
B
M
U
T
A
B
AT
A
C
A
D
M
A
U
H
A
C
AT
A
O
X
1
H
IB
C
H
P
C
C
A
A
LD
H
3A
2
A
C
A
D
S
B
A
C
A
A
2
E
H
H
A
D
H
A
LD
H
6A
1
H
M
G
C
S
2
Stage I
Stage II
Stage III
Stage IV
T1
T2
T3
Local 
invasion 
Lymph node 
invasion
Metastasis
T4
N0
N1
M0
M1
Kidney renal clear cell carcinoma n
264
57
126
81
269
69
179
11
238
17
422
79
Kidney papillary cell carcinoma
B
C
AT1
A
C
AT2
A
LD
H
9A
1
H
M
G
C
S
2
H
S
D
17B
10
A
LD
H
3A
2
M
C
C
C
2
A
LD
H
1B
1
B
C
K
D
H
A
H
A
D
H
A
B
C
K
D
H
B
H
A
D
H
B
D
B
T
B
C
AT2
H
A
D
H
E
C
H
S
1
A
C
A
D
M
IV
D
A
C
A
D
S
B
A
C
A
D
S
H
IB
A
D
H
M
U
T
P
C
C
B
A
U
H
D
LD
M
C
E
E
H
M
G
C
L
A
LD
H
2
M
C
C
C
1
H
IB
C
H
P
C
C
A
A
C
A
A
2
A
C
A
D
8
E
H
H
A
D
H
A
C
A
A
1
A
LD
H
6A
1
A
C
AT
A
O
X
1
A
B
AT
Stage I
Stage II
Stage III
Stage IV
T1
T2
T3/4
Local 
invasion 
Lymph node 
invasion
Metastasis
N0
N1/2
M0
M1
n
167
21
49
14
176
29
56
44
26
90
9
-2 2Relative gene expression
G
E
F
3
H
az
ar
d 
R
at
io
0 1
% kcal substitution
42 5
1.0
0.8
0.6
0.4
0.2
0
Replacing BCAAs
with carbohydrate
3
H
az
ar
d 
R
at
io
0 1
% kcal substitution
42 5
1.0
0.8
0.6
0.4
0.2
0
Replacing BCAAs
with fat
Ro
bu
stn
es
s
Mesothelioma
Stomach Adenocarcinoma
Adrenocortical Carcinoma
Kidney Clear Cell Carcinoma
Liver Hepatocellular Carcinoma
Cervical & Endocervical Carcinoma
Bladder Urothelial Carcinoma
Lung Adenocarcinoma
Head & Neck Squamous Carcinoma
Pancreatic Adenocarcinoma
Breast Invasive Carcinoma
Colon & Rectum Adenocarcinoma
Kidney Papilary Cell Carcinoma
Esophageal Carcinoma
Sarcoma
Acute Myeloid Leukemia
Ovarian Cystadenocarcinoma
Lung Squamous Cell Carcinoma
Glioblastoma Multiforme
Brain Lower Grade Glioma 
Uterine Carcinosarcoma
Skin Cutaneous Melanoma
Uterine Endometrioid Carcinoma
0.25 0.5 1 1052.5
Hazard Ratio ΔD
ay
s
Survival based ACADS, ACADSB, BCKDHA expression
D Significance
<0.0001
<0.001
<0.01
<0.05
>0.05
Δ Days Survival
<-1500
-1500 to -1000
-1000 to -500
-500 to -150
150 to 500
500 to 1000
-150 to 150
1000 to 1500
Robustness
HR<1
80-100%
60-80%
40-60%
20-40%
0-20%
0%
HR>1
NHANES III cancer mortality risk
1.68 (0.82-3.44)Medium (1.73-3.89%)
Adjusted HR1 Adjusted HR2
Low (<1.73%)
High (>3.89%)
Tertile
2
1
3 2.99 (1.20-7.46)
1.01.0
1.82 (0.90-3.68)
3.65 (1.62-8.24)
BCAA Intake (% kcal)
mTORC1 
BCAAs BCKDH 
BCKDK 
Metabolites
Normal & regenerating tissue Cancer
mTORC1 
BCAAs 
BCKDK 
Metabolites
Therapeutic
potential
BCKDH 
Tumor promotion
?
Net percent of cancers 
with significant change
GainLoss
Net change in expression
75
-1
00
50
-7
5
25
-5
0
0-
25
0-
25
25
-5
0
50
-7
5
75
-1
00
